[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fIbt36qV20maj80l6xhgj7kxe7KN31ymhVcBkoOcTCTk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":86,"rows":93},"ANRS, Emerging Infectious Diseases",[4],207,false,37,40,15256972,45,94,[14,17,20,23,26,29,31,34],{"name":15,"count":16},"HIV Infections",32,{"name":18,"count":19},"HIV Infection",26,{"name":21,"count":22},"HIV-1 Infection",17,{"name":24,"count":25},"HIV",14,{"name":27,"count":28},"Tuberculosis",10,{"name":30,"count":28},"HIV-1-infection",{"name":32,"count":33},"Hepatitis C",8,{"name":35,"count":33},"COVID-19",[37,42,47,52,57,62,67,72,77,81],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT05450770","Immunity to Yellow Fever in HIV-infected Patients 10 Years After a Primary Anti-yellow Fever Vaccination","2024-11-01","Yellow fever vaccination",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06302933","Negative Serology by Immunoenzymatic Test (EIA) in HIV-infected Children Treated Early With Antiretroviral in the ANRS-Pediacam Study: Pathophysiological Mechanisms","2025-08-30","Blood sampling",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT06255626","Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.","2025-09","CD40.RBDv vaccin",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06273943","Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.","2025-10-30","Cabotegravir Tablets, for oral use.",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05992077","Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia","2026-01-31","Sofosbuvir\u002FDaclatasvir",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05587894","OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial","2026-06-30","Paxlovid 5 days",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT05597735","Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease","2026-09-30","Tecovirimat",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT05813964","Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF\u002FFTC in MSM in Thailand and France.","2026-10","TDF\u002FFTC 300mg\u002F200mg fixed-dose combination",{"nctId":78,"briefTitle":79,"date":75,"intervention":80},"NCT06821126","Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults","LVT-001",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT07113106","Dose Escalation Trial of CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Healthy Volunteers","2026-10-08","CD40.Pan.CoV Low dose",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,126,144,162,180,228,251,275,293,319,337,361,379,397,420,447,472,490,508,526,552,576,594,612,635,653,679,697,723,741,761,789,807,825,843,904,922,940,958,976,994,1012,1032,1058,1076,1096,1188,1213,1231,1249,1267,1292,1310,1336,1361,1400,1435,1472,1496,1514,1538,1563,1590,1608,1626,1652,1670,1696,1714,1732,1758,1776,1794,1812,1830,1848,1874,1892,1910,1935,1953,1979,2005,2023,2050,2068,2092,2117,2142,2160,2188,2206,2234,2252,2270,2294,2321,2339,2364,2390,2408,2426,2456,2474,2492,2510,2535,2560,2578,2603,2621,2645,2672,2690,2708,2733,2755,2777,2801,2826,2844,2869,2887,2915,2939,2964,2982,3000,3023,3045,3063,3087,3110,3128,3153,3177,3200,3225,3243,3261,3283,3308,3330,3353,3379,3397,3420,3444,3469,3487,3505,3529,3547,3574,3592,3610,3628,3646,3672,3696,3714,3732,3750,3776,3794,3812,3843,3861,3879,3897,3915,3933,3951,3969,3994,4012,4030,4062,4080,4098,4116,4134,4152,4170,4188,4222,4250,4276,4299,4317,4341,4365,4387,4410,4435,4459,4484,4509,4527],{"intervention":95,"totalTrials":96,"cells":97},"ACCESS+ strategy Epclusa 400\u002F100 Oral",1,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":124},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":96,"soonestReadout":114},[109],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":120},"NCT07098481","Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy","NOT_YET_RECRUITING",[91],"2027-12-31","2028-06-30","2025-09-01",576,[119],"Hepatitis C Virus Infection",[95,121,122,123],"ACCESS+ Strategy Vosevi 400\u002F100\u002F100 Oral","Standard Strategy Vosevi 400\u002F100\u002F100 Oral","Standard Strategy Epclusa 400\u002F100 Oral",{"trials":125,"activeCount":100},[],{"intervention":121,"totalTrials":96,"cells":127},{"EARLY_PHASE1":128,"PHASE1":130,"PHASE2":132,"PHASE3":134,"PHASE4":136,"NA":142},{"trials":129,"activeCount":100},[],{"trials":131,"activeCount":100},[],{"trials":133,"activeCount":100},[],{"trials":135,"activeCount":100},[],{"trials":137,"activeCount":96,"soonestReadout":114},[138],{"nctId":110,"briefTitle":111,"status":112,"phases":139,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":140,"interventions":141},[91],[119],[95,121,122,123],{"trials":143,"activeCount":100},[],{"intervention":122,"totalTrials":96,"cells":145},{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":152,"PHASE4":154,"NA":160},{"trials":147,"activeCount":100},[],{"trials":149,"activeCount":100},[],{"trials":151,"activeCount":100},[],{"trials":153,"activeCount":100},[],{"trials":155,"activeCount":96,"soonestReadout":114},[156],{"nctId":110,"briefTitle":111,"status":112,"phases":157,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":158,"interventions":159},[91],[119],[95,121,122,123],{"trials":161,"activeCount":100},[],{"intervention":123,"totalTrials":96,"cells":163},{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":170,"PHASE4":172,"NA":178},{"trials":165,"activeCount":100},[],{"trials":167,"activeCount":100},[],{"trials":169,"activeCount":100},[],{"trials":171,"activeCount":100},[],{"trials":173,"activeCount":96,"soonestReadout":114},[174],{"nctId":110,"briefTitle":111,"status":112,"phases":175,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":176,"interventions":177},[91],[119],[95,121,122,123],{"trials":179,"activeCount":100},[],{"intervention":181,"totalTrials":182,"cells":183},"Ervebo",3,{"EARLY_PHASE1":184,"PHASE1":186,"PHASE2":188,"PHASE3":212,"PHASE4":224,"NA":226},{"trials":185,"activeCount":100},[],{"trials":187,"activeCount":100},[],{"trials":189,"activeCount":96,"soonestReadout":206},[190,202],{"nctId":191,"briefTitle":192,"status":193,"phases":194,"primaryCompletion":195,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":200},"NCT04822376","Prophylaxis Vaccine Antibodies Ebola","UNKNOWN",[89],"2022-04","2021-10-17",250,[199],"Ebola Virus Disease",[201,181],"ansuvimab",{"nctId":203,"briefTitle":204,"status":112,"phases":205,"primaryCompletion":206,"completion":206,"start":207,"enrollment":208,"conditions":209,"interventions":210},"NCT05202288","Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers",[89],"2027-08","2027-01",132,[199],[181,211],"Inmazeb",{"trials":213,"activeCount":96,"soonestReadout":218},[214],{"nctId":215,"briefTitle":216,"status":112,"phases":217,"primaryCompletion":218,"completion":219,"start":220,"enrollment":221,"conditions":222,"interventions":223},"NCT06841614","EBOla Post-Exposure Prophylaxis",[90],"2027-08-01","2028-08-01","2026-09",160,[199],[181,211],{"trials":225,"activeCount":100},[],{"trials":227,"activeCount":100},[],{"intervention":211,"totalTrials":229,"cells":230},2,{"EARLY_PHASE1":231,"PHASE1":233,"PHASE2":235,"PHASE3":241,"PHASE4":247,"NA":249},{"trials":232,"activeCount":100},[],{"trials":234,"activeCount":100},[],{"trials":236,"activeCount":96,"soonestReadout":206},[237],{"nctId":203,"briefTitle":204,"status":112,"phases":238,"primaryCompletion":206,"completion":206,"start":207,"enrollment":208,"conditions":239,"interventions":240},[89],[199],[181,211],{"trials":242,"activeCount":96,"soonestReadout":218},[243],{"nctId":215,"briefTitle":216,"status":112,"phases":244,"primaryCompletion":218,"completion":219,"start":220,"enrollment":221,"conditions":245,"interventions":246},[90],[199],[181,211],{"trials":248,"activeCount":100},[],{"trials":250,"activeCount":100},[],{"intervention":76,"totalTrials":96,"cells":252},{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":259,"PHASE4":271,"NA":273},{"trials":254,"activeCount":100},[],{"trials":256,"activeCount":100},[],{"trials":258,"activeCount":100},[],{"trials":260,"activeCount":96,"soonestReadout":75},[261],{"nctId":73,"briefTitle":74,"status":262,"phases":263,"primaryCompletion":75,"completion":264,"start":265,"enrollment":266,"conditions":267,"interventions":269},"RECRUITING",[90],"2027-05","2024-06-05",524,[268],"HIV\u002FAIDS",[76,270],"TAF\u002FFTC 25mg\u002F200mg fixed-dose combination",{"trials":272,"activeCount":100},[],{"trials":274,"activeCount":100},[],{"intervention":270,"totalTrials":96,"cells":276},{"EARLY_PHASE1":277,"PHASE1":279,"PHASE2":281,"PHASE3":283,"PHASE4":289,"NA":291},{"trials":278,"activeCount":100},[],{"trials":280,"activeCount":100},[],{"trials":282,"activeCount":100},[],{"trials":284,"activeCount":96,"soonestReadout":75},[285],{"nctId":73,"briefTitle":74,"status":262,"phases":286,"primaryCompletion":75,"completion":264,"start":265,"enrollment":266,"conditions":287,"interventions":288},[90],[268],[76,270],{"trials":290,"activeCount":100},[],{"trials":292,"activeCount":100},[],{"intervention":294,"totalTrials":96,"cells":295},"Doravirine + tenofovir DF + lamivudine",{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":300,"PHASE3":302,"PHASE4":315,"NA":317},{"trials":297,"activeCount":100},[],{"trials":299,"activeCount":100},[],{"trials":301,"activeCount":100},[],{"trials":303,"activeCount":96,"soonestReadout":308},[304],{"nctId":305,"briefTitle":306,"status":262,"phases":307,"primaryCompletion":308,"completion":309,"start":310,"enrollment":311,"conditions":312,"interventions":313},"NCT06203132","DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection",[90],"2026-11","2027-11","2025-01-27",610,[30],[294,314],"Dolutegravir + tenofovir DF + lamivudine or emtricitabine",{"trials":316,"activeCount":100},[],{"trials":318,"activeCount":100},[],{"intervention":314,"totalTrials":96,"cells":320},{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":327,"PHASE4":333,"NA":335},{"trials":322,"activeCount":100},[],{"trials":324,"activeCount":100},[],{"trials":326,"activeCount":100},[],{"trials":328,"activeCount":96,"soonestReadout":308},[329],{"nctId":305,"briefTitle":306,"status":262,"phases":330,"primaryCompletion":308,"completion":309,"start":310,"enrollment":311,"conditions":331,"interventions":332},[90],[30],[294,314],{"trials":334,"activeCount":100},[],{"trials":336,"activeCount":100},[],{"intervention":56,"totalTrials":96,"cells":338},{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":343,"PHASE3":345,"PHASE4":357,"NA":359},{"trials":340,"activeCount":100},[],{"trials":342,"activeCount":100},[],{"trials":344,"activeCount":100},[],{"trials":346,"activeCount":96,"soonestReadout":55},[347],{"nctId":53,"briefTitle":54,"status":112,"phases":348,"primaryCompletion":55,"completion":349,"start":350,"enrollment":351,"conditions":352,"interventions":354},[90],"2026-10-30","2024-04-01",322,[353],"Prevention",[56,355,356],"Cabotegravir Extended-Release Injectable Suspension, for intramuscular use.","Tenofovir disoproxil\u002FEmtricitabine 300mg\u002F200mg fixed-dose combination tablets, for oral use",{"trials":358,"activeCount":100},[],{"trials":360,"activeCount":100},[],{"intervention":355,"totalTrials":96,"cells":362},{"EARLY_PHASE1":363,"PHASE1":365,"PHASE2":367,"PHASE3":369,"PHASE4":375,"NA":377},{"trials":364,"activeCount":100},[],{"trials":366,"activeCount":100},[],{"trials":368,"activeCount":100},[],{"trials":370,"activeCount":96,"soonestReadout":55},[371],{"nctId":53,"briefTitle":54,"status":112,"phases":372,"primaryCompletion":55,"completion":349,"start":350,"enrollment":351,"conditions":373,"interventions":374},[90],[353],[56,355,356],{"trials":376,"activeCount":100},[],{"trials":378,"activeCount":100},[],{"intervention":356,"totalTrials":96,"cells":380},{"EARLY_PHASE1":381,"PHASE1":383,"PHASE2":385,"PHASE3":387,"PHASE4":393,"NA":395},{"trials":382,"activeCount":100},[],{"trials":384,"activeCount":100},[],{"trials":386,"activeCount":100},[],{"trials":388,"activeCount":96,"soonestReadout":55},[389],{"nctId":53,"briefTitle":54,"status":112,"phases":390,"primaryCompletion":55,"completion":349,"start":350,"enrollment":351,"conditions":391,"interventions":392},[90],[353],[56,355,356],{"trials":394,"activeCount":100},[],{"trials":396,"activeCount":100},[],{"intervention":71,"totalTrials":96,"cells":398},{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":403,"PHASE3":405,"PHASE4":416,"NA":418},{"trials":400,"activeCount":100},[],{"trials":402,"activeCount":100},[],{"trials":404,"activeCount":100},[],{"trials":406,"activeCount":96,"soonestReadout":70},[407],{"nctId":68,"briefTitle":69,"status":408,"phases":409,"primaryCompletion":70,"completion":70,"start":410,"enrollment":411,"conditions":412,"interventions":415},"ACTIVE_NOT_RECRUITING",[90],"2023-03-03",480,[413,414],"Monkeypox","Mpox",[71],{"trials":417,"activeCount":100},[],{"trials":419,"activeCount":100},[],{"intervention":421,"totalTrials":96,"cells":422},"Adalimumab",{"EARLY_PHASE1":423,"PHASE1":425,"PHASE2":427,"PHASE3":441,"PHASE4":443,"NA":445},{"trials":424,"activeCount":100},[],{"trials":426,"activeCount":100},[],{"trials":428,"activeCount":96,"soonestReadout":433},[429],{"nctId":430,"briefTitle":431,"status":262,"phases":432,"primaryCompletion":433,"completion":434,"start":435,"enrollment":436,"conditions":437,"interventions":440},"NCT05590455","Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis",[89],"2027-06","2027-12","2023-04-11",130,[438,439],"Tuberculous Meningitis","HIV I Infection",[421],{"trials":442,"activeCount":100},[],{"trials":444,"activeCount":100},[],{"trials":446,"activeCount":100},[],{"intervention":85,"totalTrials":96,"cells":448},{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":453,"PHASE3":466,"PHASE4":468,"NA":470},{"trials":450,"activeCount":100},[],{"trials":452,"activeCount":100},[],{"trials":454,"activeCount":96,"soonestReadout":84},[455],{"nctId":82,"briefTitle":83,"status":408,"phases":456,"primaryCompletion":84,"completion":457,"start":458,"enrollment":459,"conditions":460,"interventions":462},[88,89],"2027-06-25","2025-06-18",48,[461],"Healthy Volunteers",[85,463,464,465],"CD40.Pan.CoV Low dose (0,25mg) adjuvanted with Hiltonol®","CD40.Pan.CoV High dose","CD40.Pan.CoV High dose (1mg) adjuvanted with Hiltonol®",{"trials":467,"activeCount":100},[],{"trials":469,"activeCount":100},[],{"trials":471,"activeCount":100},[],{"intervention":463,"totalTrials":96,"cells":473},{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":484,"PHASE4":486,"NA":488},{"trials":475,"activeCount":100},[],{"trials":477,"activeCount":100},[],{"trials":479,"activeCount":96,"soonestReadout":84},[480],{"nctId":82,"briefTitle":83,"status":408,"phases":481,"primaryCompletion":84,"completion":457,"start":458,"enrollment":459,"conditions":482,"interventions":483},[88,89],[461],[85,463,464,465],{"trials":485,"activeCount":100},[],{"trials":487,"activeCount":100},[],{"trials":489,"activeCount":100},[],{"intervention":464,"totalTrials":96,"cells":491},{"EARLY_PHASE1":492,"PHASE1":494,"PHASE2":496,"PHASE3":502,"PHASE4":504,"NA":506},{"trials":493,"activeCount":100},[],{"trials":495,"activeCount":100},[],{"trials":497,"activeCount":96,"soonestReadout":84},[498],{"nctId":82,"briefTitle":83,"status":408,"phases":499,"primaryCompletion":84,"completion":457,"start":458,"enrollment":459,"conditions":500,"interventions":501},[88,89],[461],[85,463,464,465],{"trials":503,"activeCount":100},[],{"trials":505,"activeCount":100},[],{"trials":507,"activeCount":100},[],{"intervention":465,"totalTrials":96,"cells":509},{"EARLY_PHASE1":510,"PHASE1":512,"PHASE2":514,"PHASE3":520,"PHASE4":522,"NA":524},{"trials":511,"activeCount":100},[],{"trials":513,"activeCount":100},[],{"trials":515,"activeCount":96,"soonestReadout":84},[516],{"nctId":82,"briefTitle":83,"status":408,"phases":517,"primaryCompletion":84,"completion":457,"start":458,"enrollment":459,"conditions":518,"interventions":519},[88,89],[461],[85,463,464,465],{"trials":521,"activeCount":100},[],{"trials":523,"activeCount":100},[],{"trials":525,"activeCount":100},[],{"intervention":527,"totalTrials":96,"cells":528},"Recombinant human monoclonal antibody",{"EARLY_PHASE1":529,"PHASE1":531,"PHASE2":533,"PHASE3":546,"PHASE4":548,"NA":550},{"trials":530,"activeCount":100},[],{"trials":532,"activeCount":100},[],{"trials":534,"activeCount":96,"soonestReadout":539},[535],{"nctId":536,"briefTitle":537,"status":262,"phases":538,"primaryCompletion":539,"completion":540,"start":541,"enrollment":542,"conditions":543,"interventions":545},"NCT05300035","Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control",[89],"2026-12-10","2028-12-10","2024-04-11",69,[544],"HIV\u002FAIDS and Infections",[527],{"trials":547,"activeCount":100},[],{"trials":549,"activeCount":100},[],{"trials":551,"activeCount":100},[],{"intervention":66,"totalTrials":96,"cells":553},{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":570,"PHASE4":572,"NA":574},{"trials":555,"activeCount":100},[],{"trials":557,"activeCount":100},[],{"trials":559,"activeCount":96,"soonestReadout":65},[560],{"nctId":63,"briefTitle":64,"status":262,"phases":561,"primaryCompletion":65,"completion":562,"start":563,"enrollment":564,"conditions":565,"interventions":567},[89],"2027-06-30","2023-04-27",256,[35,566],"Immunodeficiency",[66,568,569],"Paxlovid 10 days","Veklury",{"trials":571,"activeCount":100},[],{"trials":573,"activeCount":100},[],{"trials":575,"activeCount":100},[],{"intervention":568,"totalTrials":96,"cells":577},{"EARLY_PHASE1":578,"PHASE1":580,"PHASE2":582,"PHASE3":588,"PHASE4":590,"NA":592},{"trials":579,"activeCount":100},[],{"trials":581,"activeCount":100},[],{"trials":583,"activeCount":96,"soonestReadout":65},[584],{"nctId":63,"briefTitle":64,"status":262,"phases":585,"primaryCompletion":65,"completion":562,"start":563,"enrollment":564,"conditions":586,"interventions":587},[89],[35,566],[66,568,569],{"trials":589,"activeCount":100},[],{"trials":591,"activeCount":100},[],{"trials":593,"activeCount":100},[],{"intervention":569,"totalTrials":96,"cells":595},{"EARLY_PHASE1":596,"PHASE1":598,"PHASE2":600,"PHASE3":606,"PHASE4":608,"NA":610},{"trials":597,"activeCount":100},[],{"trials":599,"activeCount":100},[],{"trials":601,"activeCount":96,"soonestReadout":65},[602],{"nctId":63,"briefTitle":64,"status":262,"phases":603,"primaryCompletion":65,"completion":562,"start":563,"enrollment":564,"conditions":604,"interventions":605},[89],[35,566],[66,568,569],{"trials":607,"activeCount":100},[],{"trials":609,"activeCount":100},[],{"trials":611,"activeCount":100},[],{"intervention":80,"totalTrials":96,"cells":613},{"EARLY_PHASE1":614,"PHASE1":616,"PHASE2":618,"PHASE3":629,"PHASE4":631,"NA":633},{"trials":615,"activeCount":100},[],{"trials":617,"activeCount":100},[],{"trials":619,"activeCount":96,"soonestReadout":75},[620],{"nctId":78,"briefTitle":79,"status":262,"phases":621,"primaryCompletion":75,"completion":622,"start":623,"enrollment":624,"conditions":625,"interventions":627},[88,89],"2028-03","2025-05-09",238,[626],"Healthy",[80,628],"Cormirnaty",{"trials":630,"activeCount":100},[],{"trials":632,"activeCount":100},[],{"trials":634,"activeCount":100},[],{"intervention":628,"totalTrials":96,"cells":636},{"EARLY_PHASE1":637,"PHASE1":639,"PHASE2":641,"PHASE3":647,"PHASE4":649,"NA":651},{"trials":638,"activeCount":100},[],{"trials":640,"activeCount":100},[],{"trials":642,"activeCount":96,"soonestReadout":75},[643],{"nctId":78,"briefTitle":79,"status":262,"phases":644,"primaryCompletion":75,"completion":622,"start":623,"enrollment":624,"conditions":645,"interventions":646},[88,89],[626],[80,628],{"trials":648,"activeCount":100},[],{"trials":650,"activeCount":100},[],{"trials":652,"activeCount":100},[],{"intervention":654,"totalTrials":96,"cells":655},"Baricitinib 2 MG",{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":673,"PHASE4":675,"NA":677},{"trials":657,"activeCount":100},[],{"trials":659,"activeCount":100},[],{"trials":661,"activeCount":96,"soonestReadout":666},[662],{"nctId":663,"briefTitle":664,"status":112,"phases":665,"primaryCompletion":666,"completion":667,"start":668,"enrollment":669,"conditions":670,"interventions":671},"NCT07081763","Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption",[89],"2029-05","2030-11","2026-05",191,[30],[654,672],"Sirolimus 2 MG",{"trials":674,"activeCount":100},[],{"trials":676,"activeCount":100},[],{"trials":678,"activeCount":100},[],{"intervention":672,"totalTrials":96,"cells":680},{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":685,"PHASE3":691,"PHASE4":693,"NA":695},{"trials":682,"activeCount":100},[],{"trials":684,"activeCount":100},[],{"trials":686,"activeCount":96,"soonestReadout":666},[687],{"nctId":663,"briefTitle":664,"status":112,"phases":688,"primaryCompletion":666,"completion":667,"start":668,"enrollment":669,"conditions":689,"interventions":690},[89],[30],[654,672],{"trials":692,"activeCount":100},[],{"trials":694,"activeCount":100},[],{"trials":696,"activeCount":100},[],{"intervention":698,"totalTrials":96,"cells":699},"TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI\u002Fr or INSTI",{"EARLY_PHASE1":700,"PHASE1":702,"PHASE2":704,"PHASE3":717,"PHASE4":719,"NA":721},{"trials":701,"activeCount":100},[],{"trials":703,"activeCount":100},[],{"trials":705,"activeCount":96,"soonestReadout":710},[706],{"nctId":707,"briefTitle":708,"status":112,"phases":709,"primaryCompletion":710,"completion":710,"start":711,"enrollment":712,"conditions":713,"interventions":715},"NCT06338826","Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses",[89],"2027-09-30","2025-02-01",140,[15,714],"HBV Coinfection",[698,716],"Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir",{"trials":718,"activeCount":100},[],{"trials":720,"activeCount":100},[],{"trials":722,"activeCount":100},[],{"intervention":716,"totalTrials":96,"cells":724},{"EARLY_PHASE1":725,"PHASE1":727,"PHASE2":729,"PHASE3":735,"PHASE4":737,"NA":739},{"trials":726,"activeCount":100},[],{"trials":728,"activeCount":100},[],{"trials":730,"activeCount":96,"soonestReadout":710},[731],{"nctId":707,"briefTitle":708,"status":112,"phases":732,"primaryCompletion":710,"completion":710,"start":711,"enrollment":712,"conditions":733,"interventions":734},[89],[15,714],[698,716],{"trials":736,"activeCount":100},[],{"trials":738,"activeCount":100},[],{"trials":740,"activeCount":100},[],{"intervention":51,"totalTrials":96,"cells":742},{"EARLY_PHASE1":743,"PHASE1":745,"PHASE2":747,"PHASE3":755,"PHASE4":757,"NA":759},{"trials":744,"activeCount":100},[],{"trials":746,"activeCount":100},[],{"trials":748,"activeCount":96,"soonestReadout":50},[749],{"nctId":48,"briefTitle":49,"status":262,"phases":750,"primaryCompletion":50,"completion":50,"start":751,"enrollment":752,"conditions":753,"interventions":754},[88,89],"2024-05-27",215,[35],[51],{"trials":756,"activeCount":100},[],{"trials":758,"activeCount":100},[],{"trials":760,"activeCount":100},[],{"intervention":762,"totalTrials":96,"cells":763},"CD40.RBDv vaccine adjuvanted with Hiltonol®",{"EARLY_PHASE1":764,"PHASE1":779,"PHASE2":781,"PHASE3":783,"PHASE4":785,"NA":787},{"trials":765,"activeCount":96,"soonestReadout":770},[766],{"nctId":767,"briefTitle":768,"status":262,"phases":769,"primaryCompletion":770,"completion":771,"start":772,"enrollment":459,"conditions":773,"interventions":775},"NCT07605520","An Experimental Medicine Multicenter Trial to Evaluate the Safety and Immunogenicity of Experimental Versus Authorized SARS-CoV-2 Vaccine Candidates as a Booster Dose in Healthy Participants Previously Vaccinated With Authorized mRNA SARS-CoV-2 Vaccines.",[87],"2028-05","2028-12","2026-05-13",[774],"Healthy Adults",[762,776,777,778],"CD40.Pan.CoV vaccine adjuvanted with Hiltonol®","Comirnaty® vaccine","Nuvaxovid™ vaccine",{"trials":780,"activeCount":100},[],{"trials":782,"activeCount":100},[],{"trials":784,"activeCount":100},[],{"trials":786,"activeCount":100},[],{"trials":788,"activeCount":100},[],{"intervention":776,"totalTrials":96,"cells":790},{"EARLY_PHASE1":791,"PHASE1":797,"PHASE2":799,"PHASE3":801,"PHASE4":803,"NA":805},{"trials":792,"activeCount":96,"soonestReadout":770},[793],{"nctId":767,"briefTitle":768,"status":262,"phases":794,"primaryCompletion":770,"completion":771,"start":772,"enrollment":459,"conditions":795,"interventions":796},[87],[774],[762,776,777,778],{"trials":798,"activeCount":100},[],{"trials":800,"activeCount":100},[],{"trials":802,"activeCount":100},[],{"trials":804,"activeCount":100},[],{"trials":806,"activeCount":100},[],{"intervention":777,"totalTrials":96,"cells":808},{"EARLY_PHASE1":809,"PHASE1":815,"PHASE2":817,"PHASE3":819,"PHASE4":821,"NA":823},{"trials":810,"activeCount":96,"soonestReadout":770},[811],{"nctId":767,"briefTitle":768,"status":262,"phases":812,"primaryCompletion":770,"completion":771,"start":772,"enrollment":459,"conditions":813,"interventions":814},[87],[774],[762,776,777,778],{"trials":816,"activeCount":100},[],{"trials":818,"activeCount":100},[],{"trials":820,"activeCount":100},[],{"trials":822,"activeCount":100},[],{"trials":824,"activeCount":100},[],{"intervention":778,"totalTrials":96,"cells":826},{"EARLY_PHASE1":827,"PHASE1":833,"PHASE2":835,"PHASE3":837,"PHASE4":839,"NA":841},{"trials":828,"activeCount":96,"soonestReadout":770},[829],{"nctId":767,"briefTitle":768,"status":262,"phases":830,"primaryCompletion":770,"completion":771,"start":772,"enrollment":459,"conditions":831,"interventions":832},[87],[774],[762,776,777,778],{"trials":834,"activeCount":100},[],{"trials":836,"activeCount":100},[],{"trials":838,"activeCount":100},[],{"trials":840,"activeCount":100},[],{"trials":842,"activeCount":100},[],{"intervention":46,"totalTrials":844,"cells":845},4,{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":852,"PHASE4":854,"NA":856},{"trials":847,"activeCount":100},[],{"trials":849,"activeCount":100},[],{"trials":851,"activeCount":100},[],{"trials":853,"activeCount":100},[],{"trials":855,"activeCount":100},[],{"trials":857,"activeCount":182,"soonestReadout":45},[858,878,888,894],{"nctId":859,"briefTitle":860,"status":112,"phases":861,"primaryCompletion":862,"completion":863,"start":864,"enrollment":865,"conditions":866,"interventions":871},"NCT07412977","\"Pregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort\"",[],"2033-12","2039-12","2026-02",5160,[18,867,868,869,870],"HBV Infection","HDV Infection","HCV Infection","Arbovirus Infections",[46,872,873,874,875,876,877],"Umbilical cord blood sampling","Breast milk sampling","Amniotic fluid sampling","Urine sampling","Vaginal swab","Placenta sampling",{"nctId":879,"briefTitle":880,"status":193,"phases":881,"primaryCompletion":882,"completion":50,"start":883,"enrollment":884,"conditions":885,"interventions":886},"NCT03148964","Primary Infection Cohort",[],"2024-09","1996-10",2800,[30],[887],"blood sampling",{"nctId":43,"briefTitle":44,"status":262,"phases":889,"primaryCompletion":45,"completion":45,"start":890,"enrollment":891,"conditions":892,"interventions":893},[92],"2024-05-02",451,[15],[46],{"nctId":895,"briefTitle":896,"status":262,"phases":897,"primaryCompletion":898,"completion":899,"start":900,"enrollment":901,"conditions":902,"interventions":903},"NCT01520844","the ANRS CO21 \" Extreme \" Cohort (CODEX)",[92],"2029-09","2030-09","2012-02",450,[18],[887],{"intervention":872,"totalTrials":96,"cells":905},{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":912,"PHASE4":914,"NA":916},{"trials":907,"activeCount":100},[],{"trials":909,"activeCount":100},[],{"trials":911,"activeCount":100},[],{"trials":913,"activeCount":100},[],{"trials":915,"activeCount":100},[],{"trials":917,"activeCount":96,"soonestReadout":862},[918],{"nctId":859,"briefTitle":860,"status":112,"phases":919,"primaryCompletion":862,"completion":863,"start":864,"enrollment":865,"conditions":920,"interventions":921},[],[18,867,868,869,870],[46,872,873,874,875,876,877],{"intervention":873,"totalTrials":96,"cells":923},{"EARLY_PHASE1":924,"PHASE1":926,"PHASE2":928,"PHASE3":930,"PHASE4":932,"NA":934},{"trials":925,"activeCount":100},[],{"trials":927,"activeCount":100},[],{"trials":929,"activeCount":100},[],{"trials":931,"activeCount":100},[],{"trials":933,"activeCount":100},[],{"trials":935,"activeCount":96,"soonestReadout":862},[936],{"nctId":859,"briefTitle":860,"status":112,"phases":937,"primaryCompletion":862,"completion":863,"start":864,"enrollment":865,"conditions":938,"interventions":939},[],[18,867,868,869,870],[46,872,873,874,875,876,877],{"intervention":874,"totalTrials":96,"cells":941},{"EARLY_PHASE1":942,"PHASE1":944,"PHASE2":946,"PHASE3":948,"PHASE4":950,"NA":952},{"trials":943,"activeCount":100},[],{"trials":945,"activeCount":100},[],{"trials":947,"activeCount":100},[],{"trials":949,"activeCount":100},[],{"trials":951,"activeCount":100},[],{"trials":953,"activeCount":96,"soonestReadout":862},[954],{"nctId":859,"briefTitle":860,"status":112,"phases":955,"primaryCompletion":862,"completion":863,"start":864,"enrollment":865,"conditions":956,"interventions":957},[],[18,867,868,869,870],[46,872,873,874,875,876,877],{"intervention":875,"totalTrials":96,"cells":959},{"EARLY_PHASE1":960,"PHASE1":962,"PHASE2":964,"PHASE3":966,"PHASE4":968,"NA":970},{"trials":961,"activeCount":100},[],{"trials":963,"activeCount":100},[],{"trials":965,"activeCount":100},[],{"trials":967,"activeCount":100},[],{"trials":969,"activeCount":100},[],{"trials":971,"activeCount":96,"soonestReadout":862},[972],{"nctId":859,"briefTitle":860,"status":112,"phases":973,"primaryCompletion":862,"completion":863,"start":864,"enrollment":865,"conditions":974,"interventions":975},[],[18,867,868,869,870],[46,872,873,874,875,876,877],{"intervention":876,"totalTrials":96,"cells":977},{"EARLY_PHASE1":978,"PHASE1":980,"PHASE2":982,"PHASE3":984,"PHASE4":986,"NA":988},{"trials":979,"activeCount":100},[],{"trials":981,"activeCount":100},[],{"trials":983,"activeCount":100},[],{"trials":985,"activeCount":100},[],{"trials":987,"activeCount":100},[],{"trials":989,"activeCount":96,"soonestReadout":862},[990],{"nctId":859,"briefTitle":860,"status":112,"phases":991,"primaryCompletion":862,"completion":863,"start":864,"enrollment":865,"conditions":992,"interventions":993},[],[18,867,868,869,870],[46,872,873,874,875,876,877],{"intervention":877,"totalTrials":96,"cells":995},{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1002,"PHASE4":1004,"NA":1006},{"trials":997,"activeCount":100},[],{"trials":999,"activeCount":100},[],{"trials":1001,"activeCount":100},[],{"trials":1003,"activeCount":100},[],{"trials":1005,"activeCount":100},[],{"trials":1007,"activeCount":96,"soonestReadout":862},[1008],{"nctId":859,"briefTitle":860,"status":112,"phases":1009,"primaryCompletion":862,"completion":863,"start":864,"enrollment":865,"conditions":1010,"interventions":1011},[],[18,867,868,869,870],[46,872,873,874,875,876,877],{"intervention":41,"totalTrials":96,"cells":1013},{"EARLY_PHASE1":1014,"PHASE1":1016,"PHASE2":1018,"PHASE3":1020,"PHASE4":1022,"NA":1024},{"trials":1015,"activeCount":100},[],{"trials":1017,"activeCount":100},[],{"trials":1019,"activeCount":100},[],{"trials":1021,"activeCount":100},[],{"trials":1023,"activeCount":100},[],{"trials":1025,"activeCount":96,"soonestReadout":40},[1026],{"nctId":38,"briefTitle":39,"status":112,"phases":1027,"primaryCompletion":40,"completion":40,"start":40,"enrollment":1028,"conditions":1029,"interventions":1031},[92],60,[15,1030],"Yellow Fever",[41],{"intervention":1033,"totalTrials":96,"cells":1034},"Treatment by TDF if HBcrAg RDT positive",{"EARLY_PHASE1":1035,"PHASE1":1037,"PHASE2":1039,"PHASE3":1041,"PHASE4":1043,"NA":1045},{"trials":1036,"activeCount":100},[],{"trials":1038,"activeCount":100},[],{"trials":1040,"activeCount":100},[],{"trials":1042,"activeCount":100},[],{"trials":1044,"activeCount":100},[],{"trials":1046,"activeCount":96,"soonestReadout":308},[1047],{"nctId":1048,"briefTitle":1049,"status":112,"phases":1050,"primaryCompletion":308,"completion":1051,"start":1052,"enrollment":1053,"conditions":1054,"interventions":1056},"NCT07054359","\"HBV unIversal vs Point-Of-Care-based Antiviral treatMent to Prevent Mother-to-child Transmission\"",[92],"2028-01","2025-11",3200,[867,1055],"Pregnancy",[1033,1057],"Treatment by TDF",{"intervention":1057,"totalTrials":96,"cells":1059},{"EARLY_PHASE1":1060,"PHASE1":1062,"PHASE2":1064,"PHASE3":1066,"PHASE4":1068,"NA":1070},{"trials":1061,"activeCount":100},[],{"trials":1063,"activeCount":100},[],{"trials":1065,"activeCount":100},[],{"trials":1067,"activeCount":100},[],{"trials":1069,"activeCount":100},[],{"trials":1071,"activeCount":96,"soonestReadout":308},[1072],{"nctId":1048,"briefTitle":1049,"status":112,"phases":1073,"primaryCompletion":308,"completion":1051,"start":1052,"enrollment":1053,"conditions":1074,"interventions":1075},[92],[867,1055],[1033,1057],{"intervention":61,"totalTrials":96,"cells":1077},{"EARLY_PHASE1":1078,"PHASE1":1080,"PHASE2":1082,"PHASE3":1084,"PHASE4":1086,"NA":1088},{"trials":1079,"activeCount":100},[],{"trials":1081,"activeCount":100},[],{"trials":1083,"activeCount":100},[],{"trials":1085,"activeCount":100},[],{"trials":1087,"activeCount":100},[],{"trials":1089,"activeCount":96,"soonestReadout":60},[1090],{"nctId":58,"briefTitle":59,"status":408,"phases":1091,"primaryCompletion":60,"completion":60,"start":1092,"enrollment":1093,"conditions":1094,"interventions":1095},[92],"2023-08-07",21000,[869],[61],{"intervention":1097,"totalTrials":1098,"cells":1099},"Ribavirin",6,{"EARLY_PHASE1":1100,"PHASE1":1102,"PHASE2":1104,"PHASE3":1154,"PHASE4":1169,"NA":1186},{"trials":1101,"activeCount":100},[],{"trials":1103,"activeCount":100},[],{"trials":1105,"activeCount":100},[1106,1118,1129,1142],{"nctId":1107,"briefTitle":1108,"status":1109,"phases":1110,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":19,"conditions":1114,"interventions":1115},"NCT02647632","Study to Assess Efficacy and Safety of Grazoprevir\u002FElbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir","COMPLETED",[89],"2017-01","2017-04","2016-01",[32],[1116,1117,1097],"Grazoprevir\u002FElbasvir","Sofosbuvir",{"nctId":1119,"briefTitle":1120,"status":1109,"phases":1121,"primaryCompletion":1122,"completion":1123,"start":1124,"enrollment":1125,"conditions":1126,"interventions":1127},"NCT02405013","Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir\u002FLedipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa",[89],"2017-07","2017-11","2015-10",120,[32,18],[1117,1097,1117,1128],"Ledipasvir",{"nctId":1130,"briefTitle":1131,"status":1109,"phases":1132,"primaryCompletion":1133,"completion":1134,"start":1135,"enrollment":1028,"conditions":1136,"interventions":1138},"NCT02107365","Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon\u002FRibavirin (ANRS HC32 QUATTRO)",[89],"2015-02","2015-04","2013-11",[1137],"Hepatitis C Virus Genotype 4 Infection",[1139,1140,1097,1141],"Asunaprevir","Daclatasvir","Pegylated Interferon alpha-2a",{"nctId":1143,"briefTitle":1144,"status":1109,"phases":1145,"primaryCompletion":1146,"completion":1146,"start":1147,"enrollment":1148,"conditions":1149,"interventions":1151},"NCT01332955","Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen",[89],"2013-09","2011-04",70,[1150,18],"Hepatitis C, Chronic",[1152,1153,1097],"Telaprevir","pegIFN alfa-2a",{"trials":1155,"activeCount":100},[1156],{"nctId":1157,"briefTitle":1158,"status":1109,"phases":1159,"primaryCompletion":1160,"completion":1161,"start":1162,"enrollment":1163,"conditions":1164,"interventions":1166},"NCT00323804","Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.",[89,90],"2013-02","2013-03","2006-05",372,[1150,1165],"Liver Fibrosis",[1167,1097,1168],"Peginterferon alfa-2b","Ribavirin-Placebo",{"trials":1170,"activeCount":100},[1171],{"nctId":1172,"briefTitle":1173,"status":1109,"phases":1174,"primaryCompletion":1175,"completion":1176,"start":1177,"enrollment":1178,"conditions":1179,"interventions":1182},"NCT03537196","DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)",[91],"2020-11-30","2022-12-30","2018-11-13",979,[32,1180,1181],"Drug Use","Viral Hepatitis C",[1183,1184,1097,1185],"Sofosbuvir 400 mg and Daclatasvir 60 mg","Sofosbuvir 400 mg and Daclatasvir 90 mg","Sofosbuvir and Daclatasvir for 24 weeks",{"trials":1187,"activeCount":100},[],{"intervention":1189,"totalTrials":96,"cells":1190},"Tenofovir disoproxil fumarate",{"EARLY_PHASE1":1191,"PHASE1":1193,"PHASE2":1195,"PHASE3":1197,"PHASE4":1199,"NA":1211},{"trials":1192,"activeCount":100},[],{"trials":1194,"activeCount":100},[],{"trials":1196,"activeCount":100},[],{"trials":1198,"activeCount":100},[],{"trials":1200,"activeCount":100},[1201],{"nctId":1202,"briefTitle":1203,"status":193,"phases":1204,"primaryCompletion":1205,"completion":1205,"start":1206,"enrollment":1207,"conditions":1208,"interventions":1210},"NCT02937779","Tenofovir As Prevention Of Hepatitis b Mother-to-child Transmission",[91],"2020-03-31","2017-10-04",933,[1209,1055],"Hepatitis B Chronic Infection",[1189],{"trials":1212,"activeCount":100},[],{"intervention":1183,"totalTrials":96,"cells":1214},{"EARLY_PHASE1":1215,"PHASE1":1217,"PHASE2":1219,"PHASE3":1221,"PHASE4":1223,"NA":1229},{"trials":1216,"activeCount":100},[],{"trials":1218,"activeCount":100},[],{"trials":1220,"activeCount":100},[],{"trials":1222,"activeCount":100},[],{"trials":1224,"activeCount":100},[1225],{"nctId":1172,"briefTitle":1173,"status":1109,"phases":1226,"primaryCompletion":1175,"completion":1176,"start":1177,"enrollment":1178,"conditions":1227,"interventions":1228},[91],[32,1180,1181],[1183,1184,1097,1185],{"trials":1230,"activeCount":100},[],{"intervention":1184,"totalTrials":96,"cells":1232},{"EARLY_PHASE1":1233,"PHASE1":1235,"PHASE2":1237,"PHASE3":1239,"PHASE4":1241,"NA":1247},{"trials":1234,"activeCount":100},[],{"trials":1236,"activeCount":100},[],{"trials":1238,"activeCount":100},[],{"trials":1240,"activeCount":100},[],{"trials":1242,"activeCount":100},[1243],{"nctId":1172,"briefTitle":1173,"status":1109,"phases":1244,"primaryCompletion":1175,"completion":1176,"start":1177,"enrollment":1178,"conditions":1245,"interventions":1246},[91],[32,1180,1181],[1183,1184,1097,1185],{"trials":1248,"activeCount":100},[],{"intervention":1185,"totalTrials":96,"cells":1250},{"EARLY_PHASE1":1251,"PHASE1":1253,"PHASE2":1255,"PHASE3":1257,"PHASE4":1259,"NA":1265},{"trials":1252,"activeCount":100},[],{"trials":1254,"activeCount":100},[],{"trials":1256,"activeCount":100},[],{"trials":1258,"activeCount":100},[],{"trials":1260,"activeCount":100},[1261],{"nctId":1172,"briefTitle":1173,"status":1109,"phases":1262,"primaryCompletion":1175,"completion":1176,"start":1177,"enrollment":1178,"conditions":1263,"interventions":1264},[91],[32,1180,1181],[1183,1184,1097,1185],{"trials":1266,"activeCount":100},[],{"intervention":1268,"totalTrials":96,"cells":1269},"ART",{"EARLY_PHASE1":1270,"PHASE1":1272,"PHASE2":1274,"PHASE3":1276,"PHASE4":1278,"NA":1290},{"trials":1271,"activeCount":100},[],{"trials":1273,"activeCount":100},[],{"trials":1275,"activeCount":100},[],{"trials":1277,"activeCount":100},[],{"trials":1279,"activeCount":100},[1280],{"nctId":1281,"briefTitle":1282,"status":1109,"phases":1283,"primaryCompletion":1284,"completion":1284,"start":1285,"enrollment":1286,"conditions":1287,"interventions":1288},"NCT02057796","Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts \u003C100\u002Fmm3",[91],"2018-04","2014-09",1050,[21],[1268,1289],"Rifampin, isoniazid, pyrazinamide, ethambutol",{"trials":1291,"activeCount":100},[],{"intervention":1289,"totalTrials":96,"cells":1293},{"EARLY_PHASE1":1294,"PHASE1":1296,"PHASE2":1298,"PHASE3":1300,"PHASE4":1302,"NA":1308},{"trials":1295,"activeCount":100},[],{"trials":1297,"activeCount":100},[],{"trials":1299,"activeCount":100},[],{"trials":1301,"activeCount":100},[],{"trials":1303,"activeCount":100},[1304],{"nctId":1281,"briefTitle":1282,"status":1109,"phases":1305,"primaryCompletion":1284,"completion":1284,"start":1285,"enrollment":1286,"conditions":1306,"interventions":1307},[91],[21],[1268,1289],{"trials":1309,"activeCount":100},[],{"intervention":1311,"totalTrials":96,"cells":1312},"Fumarate, Tenofovir Disoproxil",{"EARLY_PHASE1":1313,"PHASE1":1315,"PHASE2":1317,"PHASE3":1319,"PHASE4":1321,"NA":1334},{"trials":1314,"activeCount":100},[],{"trials":1316,"activeCount":100},[],{"trials":1318,"activeCount":100},[],{"trials":1320,"activeCount":100},[],{"trials":1322,"activeCount":100},[1323],{"nctId":1324,"briefTitle":1325,"status":193,"phases":1326,"primaryCompletion":1327,"completion":1328,"start":1329,"enrollment":1330,"conditions":1331,"interventions":1333},"NCT05403047","Efficacy of Tenofovir Disoproxil on Mother-to-child Transmission of HBV in Tokombéré, Cameroon in Pregnant Women",[91],"2025-07","2025-10","2022-07",150,[1332],"Hepatitis B Virus - Chronic Active",[1311],{"trials":1335,"activeCount":100},[],{"intervention":1337,"totalTrials":96,"cells":1338},"Reinforced preventive ARV therapy",{"EARLY_PHASE1":1339,"PHASE1":1341,"PHASE2":1343,"PHASE3":1345,"PHASE4":1347,"NA":1359},{"trials":1340,"activeCount":100},[],{"trials":1342,"activeCount":100},[],{"trials":1344,"activeCount":100},[],{"trials":1346,"activeCount":100},[],{"trials":1348,"activeCount":100},[1349],{"nctId":1350,"briefTitle":1351,"status":1109,"phases":1352,"primaryCompletion":1353,"completion":1353,"start":1354,"enrollment":1355,"conditions":1356,"interventions":1358},"NCT03642704","HIV Diagnosis and Treatment at Birth for Newborn With High Risk HIV Exposure",[91],"2019-09-17","2017-02-22",56,[1357],"Mother to Child HIV Transmission",[1337],{"trials":1360,"activeCount":100},[],{"intervention":1362,"totalTrials":229,"cells":1363},"dolutegravir",{"EARLY_PHASE1":1364,"PHASE1":1366,"PHASE2":1368,"PHASE3":1370,"PHASE4":1396,"NA":1398},{"trials":1365,"activeCount":100},[],{"trials":1367,"activeCount":100},[],{"trials":1369,"activeCount":100},[],{"trials":1371,"activeCount":100},[1372,1383],{"nctId":1373,"briefTitle":1374,"status":193,"phases":1375,"primaryCompletion":1376,"completion":1376,"start":1377,"enrollment":411,"conditions":1378,"interventions":1379},"NCT04022967","ANRS 12372 MODERATO Study",[90],"2025-02-05","2020-09-21",[30],[1362,1380,1381,1382],"atazanavir boosted with ritonavir","tenofovir + lamivudine +efavirenz or dolutegravir + lamivudine + tenofovir","Lamivudine",{"nctId":1384,"briefTitle":1385,"status":1109,"phases":1386,"primaryCompletion":1387,"completion":1388,"start":1389,"enrollment":1390,"conditions":1391,"interventions":1392},"NCT02987530","National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) Infection",[90],"2019-07-30","2020-01-31","2017-04-11",101,[21],[1393,1394,1395],"Dolutegravir","Darunavir-cobicistat","Emtricitabine-Tenofovir",{"trials":1397,"activeCount":100},[],{"trials":1399,"activeCount":100},[],{"intervention":1401,"totalTrials":229,"cells":1402},"Lamivudine Oral Solution",{"EARLY_PHASE1":1403,"PHASE1":1405,"PHASE2":1407,"PHASE3":1419,"PHASE4":1431,"NA":1433},{"trials":1404,"activeCount":100},[],{"trials":1406,"activeCount":100},[],{"trials":1408,"activeCount":100},[1409],{"nctId":1410,"briefTitle":1411,"status":193,"phases":1412,"primaryCompletion":1413,"completion":1413,"start":1414,"enrollment":1415,"conditions":1416,"interventions":1418},"NCT03869944","Preventing Childhood HIV: Rescue Intervention. ANRS 12388 PREVENIR-PEV",[89],"2022-03","2019-12-04",97,[1417],"HIV-1",[1401],{"trials":1420,"activeCount":100},[1421],{"nctId":1422,"briefTitle":1423,"status":1109,"phases":1424,"primaryCompletion":1425,"completion":1426,"start":1427,"enrollment":1428,"conditions":1429,"interventions":1430},"NCT03870438","Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention",[90],"2022-09-12","2022-10-31","2019-12-14",1506,[1417],[1401],{"trials":1432,"activeCount":100},[],{"trials":1434,"activeCount":100},[],{"intervention":1436,"totalTrials":229,"cells":1437},"raltegravir",{"EARLY_PHASE1":1438,"PHASE1":1440,"PHASE2":1442,"PHASE3":1455,"PHASE4":1468,"NA":1470},{"trials":1439,"activeCount":100},[],{"trials":1441,"activeCount":100},[],{"trials":1443,"activeCount":100},[1444],{"nctId":1445,"briefTitle":1446,"status":1109,"phases":1447,"primaryCompletion":1448,"completion":1449,"start":1450,"enrollment":1451,"conditions":1452,"interventions":1453},"NCT00822315","Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis",[89],"2011-11","2012-05","2009-07",155,[15,27],[1454,1436,1436],"efavirenz",{"trials":1456,"activeCount":100},[1457],{"nctId":1458,"briefTitle":1459,"status":1109,"phases":1460,"primaryCompletion":1461,"completion":1461,"start":1462,"enrollment":1463,"conditions":1464,"interventions":1466},"NCT01453192","Renal Transplantation and Raltegravir in HIV-Infected Patients",[90],"2015-11","2011-12",27,[21,1465],"Chronic Renal Insufficiency",[1467],"Raltegravir",{"trials":1469,"activeCount":100},[],{"trials":1471,"activeCount":100},[],{"intervention":1473,"totalTrials":96,"cells":1474},"AZT-3TC-LPV\u002Fr twice a day",{"EARLY_PHASE1":1475,"PHASE1":1477,"PHASE2":1479,"PHASE3":1481,"PHASE4":1492,"NA":1494},{"trials":1476,"activeCount":100},[],{"trials":1478,"activeCount":100},[],{"trials":1480,"activeCount":100},[],{"trials":1482,"activeCount":100},[1483],{"nctId":1484,"briefTitle":1485,"status":1109,"phases":1486,"primaryCompletion":1134,"completion":1134,"start":1487,"enrollment":1488,"conditions":1489,"interventions":1490},"NCT01127204","Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age",[89,90],"2011-06",161,[15],[1473,1491],"ABC-3TC-EFV once a day",{"trials":1493,"activeCount":100},[],{"trials":1495,"activeCount":100},[],{"intervention":1491,"totalTrials":96,"cells":1497},{"EARLY_PHASE1":1498,"PHASE1":1500,"PHASE2":1502,"PHASE3":1504,"PHASE4":1510,"NA":1512},{"trials":1499,"activeCount":100},[],{"trials":1501,"activeCount":100},[],{"trials":1503,"activeCount":100},[],{"trials":1505,"activeCount":100},[1506],{"nctId":1484,"briefTitle":1485,"status":1109,"phases":1507,"primaryCompletion":1134,"completion":1134,"start":1487,"enrollment":1488,"conditions":1508,"interventions":1509},[89,90],[15],[1473,1491],{"trials":1511,"activeCount":100},[],{"trials":1513,"activeCount":100},[],{"intervention":1515,"totalTrials":96,"cells":1516},"GenHevac-B",{"EARLY_PHASE1":1517,"PHASE1":1519,"PHASE2":1521,"PHASE3":1523,"PHASE4":1534,"NA":1536},{"trials":1518,"activeCount":100},[],{"trials":1520,"activeCount":100},[],{"trials":1522,"activeCount":100},[],{"trials":1524,"activeCount":100},[1525],{"nctId":1526,"briefTitle":1527,"status":1109,"phases":1528,"primaryCompletion":1462,"completion":1160,"start":1529,"enrollment":1530,"conditions":1531,"interventions":1533},"NCT00670839","Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST)",[90],"2008-05",178,[1532,18],"Hepatitis B",[1515,1515],{"trials":1535,"activeCount":100},[],{"trials":1537,"activeCount":100},[],{"intervention":1539,"totalTrials":96,"cells":1540},"Maraviroc",{"EARLY_PHASE1":1541,"PHASE1":1543,"PHASE2":1545,"PHASE3":1547,"PHASE4":1559,"NA":1561},{"trials":1542,"activeCount":100},[],{"trials":1544,"activeCount":100},[],{"trials":1546,"activeCount":100},[],{"trials":1548,"activeCount":100},[1549],{"nctId":1550,"briefTitle":1551,"status":1109,"phases":1552,"primaryCompletion":1553,"completion":1553,"start":1554,"enrollment":1555,"conditions":1556,"interventions":1558},"NCT01348308","Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients",[90],"2016-03","2011-09",407,[21,1557],"AIDS",[1539],{"trials":1560,"activeCount":100},[],{"trials":1562,"activeCount":100},[],{"intervention":1564,"totalTrials":96,"cells":1565},"Dolutegravir 50 mg",{"EARLY_PHASE1":1566,"PHASE1":1568,"PHASE2":1570,"PHASE3":1572,"PHASE4":1586,"NA":1588},{"trials":1567,"activeCount":100},[],{"trials":1569,"activeCount":100},[],{"trials":1571,"activeCount":100},[],{"trials":1573,"activeCount":100},[1574],{"nctId":1575,"briefTitle":1576,"status":1109,"phases":1577,"primaryCompletion":1578,"completion":1579,"start":1580,"enrollment":1581,"conditions":1582,"interventions":1583},"NCT02777229","Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings",[90],"2018-07","2021-07","2016-07",616,[21],[1564,1584,1585],"Tenofovir disoproxil fumarate 300 mg \u002F lamivudine 300 mg","Efavirenz 400 mg",{"trials":1587,"activeCount":100},[],{"trials":1589,"activeCount":100},[],{"intervention":1584,"totalTrials":96,"cells":1591},{"EARLY_PHASE1":1592,"PHASE1":1594,"PHASE2":1596,"PHASE3":1598,"PHASE4":1604,"NA":1606},{"trials":1593,"activeCount":100},[],{"trials":1595,"activeCount":100},[],{"trials":1597,"activeCount":100},[],{"trials":1599,"activeCount":100},[1600],{"nctId":1575,"briefTitle":1576,"status":1109,"phases":1601,"primaryCompletion":1578,"completion":1579,"start":1580,"enrollment":1581,"conditions":1602,"interventions":1603},[90],[21],[1564,1584,1585],{"trials":1605,"activeCount":100},[],{"trials":1607,"activeCount":100},[],{"intervention":1585,"totalTrials":96,"cells":1609},{"EARLY_PHASE1":1610,"PHASE1":1612,"PHASE2":1614,"PHASE3":1616,"PHASE4":1622,"NA":1624},{"trials":1611,"activeCount":100},[],{"trials":1613,"activeCount":100},[],{"trials":1615,"activeCount":100},[],{"trials":1617,"activeCount":100},[1618],{"nctId":1575,"briefTitle":1576,"status":1109,"phases":1619,"primaryCompletion":1578,"completion":1579,"start":1580,"enrollment":1581,"conditions":1620,"interventions":1621},[90],[21],[1564,1584,1585],{"trials":1623,"activeCount":100},[],{"trials":1625,"activeCount":100},[],{"intervention":1627,"totalTrials":96,"cells":1628},"Intensified TB treatment",{"EARLY_PHASE1":1629,"PHASE1":1631,"PHASE2":1633,"PHASE3":1635,"PHASE4":1648,"NA":1650},{"trials":1630,"activeCount":100},[],{"trials":1632,"activeCount":100},[],{"trials":1634,"activeCount":100},[],{"trials":1636,"activeCount":100},[1637],{"nctId":1638,"briefTitle":1639,"status":1109,"phases":1640,"primaryCompletion":1641,"completion":1641,"start":1642,"enrollment":1643,"conditions":1644,"interventions":1646},"NCT04738812","Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression",[90],"2025-11-12","2022-04-21",1330,[27,30,1645],"Immuno-Deficiency",[1627,1647],"WHO standard TB treatment",{"trials":1649,"activeCount":100},[],{"trials":1651,"activeCount":100},[],{"intervention":1647,"totalTrials":96,"cells":1653},{"EARLY_PHASE1":1654,"PHASE1":1656,"PHASE2":1658,"PHASE3":1660,"PHASE4":1666,"NA":1668},{"trials":1655,"activeCount":100},[],{"trials":1657,"activeCount":100},[],{"trials":1659,"activeCount":100},[],{"trials":1661,"activeCount":100},[1662],{"nctId":1638,"briefTitle":1639,"status":1109,"phases":1663,"primaryCompletion":1641,"completion":1641,"start":1642,"enrollment":1643,"conditions":1664,"interventions":1665},[90],[27,30,1645],[1627,1647],{"trials":1667,"activeCount":100},[],{"trials":1669,"activeCount":100},[],{"intervention":1671,"totalTrials":96,"cells":1672},"Aspirin",{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1679,"PHASE4":1692,"NA":1694},{"trials":1674,"activeCount":100},[],{"trials":1676,"activeCount":100},[],{"trials":1678,"activeCount":100},[],{"trials":1680,"activeCount":100},[1681],{"nctId":1682,"briefTitle":1683,"status":193,"phases":1684,"primaryCompletion":50,"completion":1685,"start":1686,"enrollment":1687,"conditions":1688,"interventions":1689},"NCT04145258","Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis",[90],"2026-04","2021-02-07",768,[438],[1671,1690,1691],"WHO TBM treatment","Intensified TBM treatment",{"trials":1693,"activeCount":100},[],{"trials":1695,"activeCount":100},[],{"intervention":1690,"totalTrials":96,"cells":1697},{"EARLY_PHASE1":1698,"PHASE1":1700,"PHASE2":1702,"PHASE3":1704,"PHASE4":1710,"NA":1712},{"trials":1699,"activeCount":100},[],{"trials":1701,"activeCount":100},[],{"trials":1703,"activeCount":100},[],{"trials":1705,"activeCount":100},[1706],{"nctId":1682,"briefTitle":1683,"status":193,"phases":1707,"primaryCompletion":50,"completion":1685,"start":1686,"enrollment":1687,"conditions":1708,"interventions":1709},[90],[438],[1671,1690,1691],{"trials":1711,"activeCount":100},[],{"trials":1713,"activeCount":100},[],{"intervention":1691,"totalTrials":96,"cells":1715},{"EARLY_PHASE1":1716,"PHASE1":1718,"PHASE2":1720,"PHASE3":1722,"PHASE4":1728,"NA":1730},{"trials":1717,"activeCount":100},[],{"trials":1719,"activeCount":100},[],{"trials":1721,"activeCount":100},[],{"trials":1723,"activeCount":100},[1724],{"nctId":1682,"briefTitle":1683,"status":193,"phases":1725,"primaryCompletion":50,"completion":1685,"start":1686,"enrollment":1687,"conditions":1726,"interventions":1727},[90],[438],[1671,1690,1691],{"trials":1729,"activeCount":100},[],{"trials":1731,"activeCount":100},[],{"intervention":1733,"totalTrials":96,"cells":1734},"Flucytosine",{"EARLY_PHASE1":1735,"PHASE1":1737,"PHASE2":1739,"PHASE3":1741,"PHASE4":1754,"NA":1756},{"trials":1736,"activeCount":100},[],{"trials":1738,"activeCount":100},[],{"trials":1740,"activeCount":100},[],{"trials":1742,"activeCount":100},[1743],{"nctId":1744,"briefTitle":1745,"status":193,"phases":1746,"primaryCompletion":1747,"completion":1748,"start":1449,"enrollment":1749,"conditions":1750,"interventions":1752},"NCT01715922","Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa",[89,90],"2015-09","2016-09",41,[1751,24],"Cryptococcal Meningitis",[1753,1733],"Fluconazole",{"trials":1755,"activeCount":100},[],{"trials":1757,"activeCount":100},[],{"intervention":1380,"totalTrials":96,"cells":1759},{"EARLY_PHASE1":1760,"PHASE1":1762,"PHASE2":1764,"PHASE3":1766,"PHASE4":1772,"NA":1774},{"trials":1761,"activeCount":100},[],{"trials":1763,"activeCount":100},[],{"trials":1765,"activeCount":100},[],{"trials":1767,"activeCount":100},[1768],{"nctId":1373,"briefTitle":1374,"status":193,"phases":1769,"primaryCompletion":1376,"completion":1376,"start":1377,"enrollment":411,"conditions":1770,"interventions":1771},[90],[30],[1362,1380,1381,1382],{"trials":1773,"activeCount":100},[],{"trials":1775,"activeCount":100},[],{"intervention":1381,"totalTrials":96,"cells":1777},{"EARLY_PHASE1":1778,"PHASE1":1780,"PHASE2":1782,"PHASE3":1784,"PHASE4":1790,"NA":1792},{"trials":1779,"activeCount":100},[],{"trials":1781,"activeCount":100},[],{"trials":1783,"activeCount":100},[],{"trials":1785,"activeCount":100},[1786],{"nctId":1373,"briefTitle":1374,"status":193,"phases":1787,"primaryCompletion":1376,"completion":1376,"start":1377,"enrollment":411,"conditions":1788,"interventions":1789},[90],[30],[1362,1380,1381,1382],{"trials":1791,"activeCount":100},[],{"trials":1793,"activeCount":100},[],{"intervention":1382,"totalTrials":96,"cells":1795},{"EARLY_PHASE1":1796,"PHASE1":1798,"PHASE2":1800,"PHASE3":1802,"PHASE4":1808,"NA":1810},{"trials":1797,"activeCount":100},[],{"trials":1799,"activeCount":100},[],{"trials":1801,"activeCount":100},[],{"trials":1803,"activeCount":100},[1804],{"nctId":1373,"briefTitle":1374,"status":193,"phases":1805,"primaryCompletion":1376,"completion":1376,"start":1377,"enrollment":411,"conditions":1806,"interventions":1807},[90],[30],[1362,1380,1381,1382],{"trials":1809,"activeCount":100},[],{"trials":1811,"activeCount":100},[],{"intervention":1394,"totalTrials":96,"cells":1813},{"EARLY_PHASE1":1814,"PHASE1":1816,"PHASE2":1818,"PHASE3":1820,"PHASE4":1826,"NA":1828},{"trials":1815,"activeCount":100},[],{"trials":1817,"activeCount":100},[],{"trials":1819,"activeCount":100},[],{"trials":1821,"activeCount":100},[1822],{"nctId":1384,"briefTitle":1385,"status":1109,"phases":1823,"primaryCompletion":1387,"completion":1388,"start":1389,"enrollment":1390,"conditions":1824,"interventions":1825},[90],[21],[1393,1394,1395],{"trials":1827,"activeCount":100},[],{"trials":1829,"activeCount":100},[],{"intervention":1395,"totalTrials":96,"cells":1831},{"EARLY_PHASE1":1832,"PHASE1":1834,"PHASE2":1836,"PHASE3":1838,"PHASE4":1844,"NA":1846},{"trials":1833,"activeCount":100},[],{"trials":1835,"activeCount":100},[],{"trials":1837,"activeCount":100},[],{"trials":1839,"activeCount":100},[1840],{"nctId":1384,"briefTitle":1385,"status":1109,"phases":1841,"primaryCompletion":1387,"completion":1388,"start":1389,"enrollment":1390,"conditions":1842,"interventions":1843},[90],[21],[1393,1394,1395],{"trials":1845,"activeCount":100},[],{"trials":1847,"activeCount":100},[],{"intervention":1849,"totalTrials":96,"cells":1850},"Varenicline",{"EARLY_PHASE1":1851,"PHASE1":1853,"PHASE2":1855,"PHASE3":1857,"PHASE4":1870,"NA":1872},{"trials":1852,"activeCount":100},[],{"trials":1854,"activeCount":100},[],{"trials":1856,"activeCount":100},[],{"trials":1858,"activeCount":100},[1859],{"nctId":1860,"briefTitle":1861,"status":1109,"phases":1862,"primaryCompletion":1863,"completion":1864,"start":1865,"enrollment":1866,"conditions":1867,"interventions":1869},"NCT00918307","Efficacy and Safety of Varenicline Among HIV-infected Patients",[90],"2014-01","2014-07","2009-10",248,[15,1868],"Tobacco Dependence",[1849],{"trials":1871,"activeCount":100},[],{"trials":1873,"activeCount":100},[],{"intervention":1167,"totalTrials":96,"cells":1875},{"EARLY_PHASE1":1876,"PHASE1":1878,"PHASE2":1880,"PHASE3":1882,"PHASE4":1888,"NA":1890},{"trials":1877,"activeCount":100},[],{"trials":1879,"activeCount":100},[],{"trials":1881,"activeCount":100},[],{"trials":1883,"activeCount":100},[1884],{"nctId":1157,"briefTitle":1158,"status":1109,"phases":1885,"primaryCompletion":1160,"completion":1161,"start":1162,"enrollment":1163,"conditions":1886,"interventions":1887},[89,90],[1150,1165],[1167,1097,1168],{"trials":1889,"activeCount":100},[],{"trials":1891,"activeCount":100},[],{"intervention":1168,"totalTrials":96,"cells":1893},{"EARLY_PHASE1":1894,"PHASE1":1896,"PHASE2":1898,"PHASE3":1900,"PHASE4":1906,"NA":1908},{"trials":1895,"activeCount":100},[],{"trials":1897,"activeCount":100},[],{"trials":1899,"activeCount":100},[],{"trials":1901,"activeCount":100},[1902],{"nctId":1157,"briefTitle":1158,"status":1109,"phases":1903,"primaryCompletion":1160,"completion":1161,"start":1162,"enrollment":1163,"conditions":1904,"interventions":1905},[89,90],[1150,1165],[1167,1097,1168],{"trials":1907,"activeCount":100},[],{"trials":1909,"activeCount":100},[],{"intervention":1911,"totalTrials":96,"cells":1912},"Tenofovir + lamivudine + raltegravir",{"EARLY_PHASE1":1913,"PHASE1":1915,"PHASE2":1917,"PHASE3":1919,"PHASE4":1931,"NA":1933},{"trials":1914,"activeCount":100},[],{"trials":1916,"activeCount":100},[],{"trials":1918,"activeCount":100},[],{"trials":1920,"activeCount":100},[1921],{"nctId":1922,"briefTitle":1923,"status":1109,"phases":1924,"primaryCompletion":1925,"completion":1925,"start":1926,"enrollment":1927,"conditions":1928,"interventions":1929},"NCT02273765","Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis",[90],"2018-11-28","2015-09-11",460,[21,27],[1911,1930],"Tenofovir + lamivudine + efavirenz",{"trials":1932,"activeCount":100},[],{"trials":1934,"activeCount":100},[],{"intervention":1930,"totalTrials":96,"cells":1936},{"EARLY_PHASE1":1937,"PHASE1":1939,"PHASE2":1941,"PHASE3":1943,"PHASE4":1949,"NA":1951},{"trials":1938,"activeCount":100},[],{"trials":1940,"activeCount":100},[],{"trials":1942,"activeCount":100},[],{"trials":1944,"activeCount":100},[1945],{"nctId":1922,"briefTitle":1923,"status":1109,"phases":1946,"primaryCompletion":1925,"completion":1925,"start":1926,"enrollment":1927,"conditions":1947,"interventions":1948},[90],[21,27],[1911,1930],{"trials":1950,"activeCount":100},[],{"trials":1952,"activeCount":100},[],{"intervention":1954,"totalTrials":96,"cells":1955},"131 I-lipiodol",{"EARLY_PHASE1":1956,"PHASE1":1958,"PHASE2":1960,"PHASE3":1962,"PHASE4":1975,"NA":1977},{"trials":1957,"activeCount":100},[],{"trials":1959,"activeCount":100},[],{"trials":1961,"activeCount":100},[],{"trials":1963,"activeCount":100},[1964],{"nctId":1965,"briefTitle":1966,"status":1109,"phases":1967,"primaryCompletion":1968,"completion":1968,"start":1969,"enrollment":1970,"conditions":1971,"interventions":1974},"NCT00116454","Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis",[90],"2013-08","2005-07",73,[1972,1973],"Carcinoma, Hepatocellular","Hepatitis, Viral, Human",[1954],{"trials":1976,"activeCount":100},[],{"trials":1978,"activeCount":100},[],{"intervention":1980,"totalTrials":96,"cells":1981},"monoPI - boosted lopinavir or boosted darunavir",{"EARLY_PHASE1":1982,"PHASE1":1984,"PHASE2":1986,"PHASE3":1988,"PHASE4":2001,"NA":2003},{"trials":1983,"activeCount":100},[],{"trials":1985,"activeCount":100},[],{"trials":1987,"activeCount":100},[],{"trials":1989,"activeCount":100},[1990],{"nctId":1991,"briefTitle":1992,"status":1109,"phases":1993,"primaryCompletion":1994,"completion":1995,"start":1996,"enrollment":1997,"conditions":1998,"interventions":1999},"NCT01905059","Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa",[90],"2016-04","2017-02","2014-02",265,[18],[1980,2000],"bi therapy - (boosted lopinavir or boosted darunavir) + lamivudine",{"trials":2002,"activeCount":100},[],{"trials":2004,"activeCount":100},[],{"intervention":2000,"totalTrials":96,"cells":2006},{"EARLY_PHASE1":2007,"PHASE1":2009,"PHASE2":2011,"PHASE3":2013,"PHASE4":2019,"NA":2021},{"trials":2008,"activeCount":100},[],{"trials":2010,"activeCount":100},[],{"trials":2012,"activeCount":100},[],{"trials":2014,"activeCount":100},[2015],{"nctId":1991,"briefTitle":1992,"status":1109,"phases":2016,"primaryCompletion":1994,"completion":1995,"start":1996,"enrollment":1997,"conditions":2017,"interventions":2018},[90],[18],[1980,2000],{"trials":2020,"activeCount":100},[],{"trials":2022,"activeCount":100},[],{"intervention":2024,"totalTrials":96,"cells":2025},"raltegravir; maraviroc; darunavir; ritonavir; tenofovir\u002Femtricitabine",{"EARLY_PHASE1":2026,"PHASE1":2028,"PHASE2":2030,"PHASE3":2032,"PHASE4":2046,"NA":2048},{"trials":2027,"activeCount":100},[],{"trials":2029,"activeCount":100},[],{"trials":2031,"activeCount":100},[],{"trials":2033,"activeCount":100},[2034],{"nctId":2035,"briefTitle":2036,"status":1109,"phases":2037,"primaryCompletion":2038,"completion":2039,"start":2040,"enrollment":2041,"conditions":2042,"interventions":2044},"NCT01033760","Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)",[90],"2013-07","2013-12","2010-04",90,[2043],"HIV-1 Infections",[2024,2045],"darunavir; ritonavir; emtricitabine\u002Ftenofovir",{"trials":2047,"activeCount":100},[],{"trials":2049,"activeCount":100},[],{"intervention":2045,"totalTrials":96,"cells":2051},{"EARLY_PHASE1":2052,"PHASE1":2054,"PHASE2":2056,"PHASE3":2058,"PHASE4":2064,"NA":2066},{"trials":2053,"activeCount":100},[],{"trials":2055,"activeCount":100},[],{"trials":2057,"activeCount":100},[],{"trials":2059,"activeCount":100},[2060],{"nctId":2035,"briefTitle":2036,"status":1109,"phases":2061,"primaryCompletion":2038,"completion":2039,"start":2040,"enrollment":2041,"conditions":2062,"interventions":2063},[90],[2043],[2024,2045],{"trials":2065,"activeCount":100},[],{"trials":2067,"activeCount":100},[],{"intervention":2069,"totalTrials":96,"cells":2070},"Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin",{"EARLY_PHASE1":2071,"PHASE1":2073,"PHASE2":2075,"PHASE3":2077,"PHASE4":2088,"NA":2090},{"trials":2072,"activeCount":100},[],{"trials":2074,"activeCount":100},[],{"trials":2076,"activeCount":100},[],{"trials":2078,"activeCount":100},[2079],{"nctId":2080,"briefTitle":2081,"status":2082,"phases":2083,"primaryCompletion":2084,"completion":2084,"start":2084,"enrollment":100,"conditions":2085,"interventions":2087},"NCT02099604","Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C","WITHDRAWN",[90],"2014-04",[2086],"Chronic Hepatitis C",[2069],{"trials":2089,"activeCount":100},[],{"trials":2091,"activeCount":100},[],{"intervention":2093,"totalTrials":96,"cells":2094},"Treatment discontinuation",{"EARLY_PHASE1":2095,"PHASE1":2097,"PHASE2":2099,"PHASE3":2101,"PHASE4":2113,"NA":2115},{"trials":2096,"activeCount":100},[],{"trials":2098,"activeCount":100},[],{"trials":2100,"activeCount":100},[],{"trials":2102,"activeCount":100},[2103],{"nctId":2104,"briefTitle":2105,"status":1109,"phases":2106,"primaryCompletion":2107,"completion":2108,"start":2109,"enrollment":2110,"conditions":2111,"interventions":2112},"NCT03256422","Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7\u002F7 Days Per Week in HIV-1 Infected Patients",[90],"2019-08-06","2020-03-02","2017-09-07",640,[15],[2093],{"trials":2114,"activeCount":100},[],{"trials":2116,"activeCount":100},[],{"intervention":2118,"totalTrials":96,"cells":2119},"Lopinavir",{"EARLY_PHASE1":2120,"PHASE1":2122,"PHASE2":2124,"PHASE3":2126,"PHASE4":2138,"NA":2140},{"trials":2121,"activeCount":100},[],{"trials":2123,"activeCount":100},[],{"trials":2125,"activeCount":100},[],{"trials":2127,"activeCount":100},[2128],{"nctId":2129,"briefTitle":2130,"status":2082,"phases":2131,"primaryCompletion":2132,"completion":2133,"start":2134,"enrollment":100,"conditions":2135,"interventions":2136},"NCT01255371","A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir\u002FRitonavir",[90],"2013-05","2014-12","2012-03",[24],[2118,2137],"Atazanavir",{"trials":2139,"activeCount":100},[],{"trials":2141,"activeCount":100},[],{"intervention":2137,"totalTrials":96,"cells":2143},{"EARLY_PHASE1":2144,"PHASE1":2146,"PHASE2":2148,"PHASE3":2150,"PHASE4":2156,"NA":2158},{"trials":2145,"activeCount":100},[],{"trials":2147,"activeCount":100},[],{"trials":2149,"activeCount":100},[],{"trials":2151,"activeCount":100},[2152],{"nctId":2129,"briefTitle":2130,"status":2082,"phases":2153,"primaryCompletion":2132,"completion":2133,"start":2134,"enrollment":100,"conditions":2154,"interventions":2155},[90],[24],[2118,2137],{"trials":2157,"activeCount":100},[],{"trials":2159,"activeCount":100},[],{"intervention":2161,"totalTrials":96,"cells":2162},"Experimental: doxycycline",{"EARLY_PHASE1":2163,"PHASE1":2165,"PHASE2":2167,"PHASE3":2169,"PHASE4":2184,"NA":2186},{"trials":2164,"activeCount":100},[],{"trials":2166,"activeCount":100},[],{"trials":2168,"activeCount":100},[],{"trials":2170,"activeCount":100},[2171],{"nctId":2172,"briefTitle":2173,"status":1109,"phases":2174,"primaryCompletion":2175,"completion":2176,"start":2177,"enrollment":2178,"conditions":2179,"interventions":2182},"NCT04597424","Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate\u002F Emtricitabine (TDF\u002FFTC) for HIV Pre-Exposure Prophylaxis (PrEP)",[90],"2023-02-19","2024-04-19","2021-01-19",556,[2180,2181],"Unsafe Sex","Risk-Taking",[2161,2183],"Bexsero® vaccine",{"trials":2185,"activeCount":100},[],{"trials":2187,"activeCount":100},[],{"intervention":2183,"totalTrials":96,"cells":2189},{"EARLY_PHASE1":2190,"PHASE1":2192,"PHASE2":2194,"PHASE3":2196,"PHASE4":2202,"NA":2204},{"trials":2191,"activeCount":100},[],{"trials":2193,"activeCount":100},[],{"trials":2195,"activeCount":100},[],{"trials":2197,"activeCount":100},[2198],{"nctId":2172,"briefTitle":2173,"status":1109,"phases":2199,"primaryCompletion":2175,"completion":2176,"start":2177,"enrollment":2178,"conditions":2200,"interventions":2201},[90],[2180,2181],[2161,2183],{"trials":2203,"activeCount":100},[],{"trials":2205,"activeCount":100},[],{"intervention":2207,"totalTrials":96,"cells":2208},"Lopinavir\u002FRitonavir 200 MG-50 MG Oral",{"EARLY_PHASE1":2209,"PHASE1":2211,"PHASE2":2213,"PHASE3":2215,"PHASE4":2230,"NA":2232},{"trials":2210,"activeCount":100},[],{"trials":2212,"activeCount":100},[],{"trials":2214,"activeCount":100},[],{"trials":2216,"activeCount":100},[2217],{"nctId":2218,"briefTitle":2219,"status":1109,"phases":2220,"primaryCompletion":2221,"completion":2221,"start":2222,"enrollment":2223,"conditions":2224,"interventions":2227},"NCT04466241","Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial",[89,90],"2021-11-01","2020-11-27",294,[35,2225,2226],"COVID-19 Drug Treatment","Severe Acute Respiratory Syndrome Coronavirus 2",[2207,2228,2229],"Telmisartan 40Mg Oral","Atorvastatin 20 Mg Oral",{"trials":2231,"activeCount":100},[],{"trials":2233,"activeCount":100},[],{"intervention":2228,"totalTrials":96,"cells":2235},{"EARLY_PHASE1":2236,"PHASE1":2238,"PHASE2":2240,"PHASE3":2242,"PHASE4":2248,"NA":2250},{"trials":2237,"activeCount":100},[],{"trials":2239,"activeCount":100},[],{"trials":2241,"activeCount":100},[],{"trials":2243,"activeCount":100},[2244],{"nctId":2218,"briefTitle":2219,"status":1109,"phases":2245,"primaryCompletion":2221,"completion":2221,"start":2222,"enrollment":2223,"conditions":2246,"interventions":2247},[89,90],[35,2225,2226],[2207,2228,2229],{"trials":2249,"activeCount":100},[],{"trials":2251,"activeCount":100},[],{"intervention":2229,"totalTrials":96,"cells":2253},{"EARLY_PHASE1":2254,"PHASE1":2256,"PHASE2":2258,"PHASE3":2260,"PHASE4":2266,"NA":2268},{"trials":2255,"activeCount":100},[],{"trials":2257,"activeCount":100},[],{"trials":2259,"activeCount":100},[],{"trials":2261,"activeCount":100},[2262],{"nctId":2218,"briefTitle":2219,"status":1109,"phases":2263,"primaryCompletion":2221,"completion":2221,"start":2222,"enrollment":2223,"conditions":2264,"interventions":2265},[89,90],[35,2225,2226],[2207,2228,2229],{"trials":2267,"activeCount":100},[],{"trials":2269,"activeCount":100},[],{"intervention":2271,"totalTrials":96,"cells":2272},"Irbesartan",{"EARLY_PHASE1":2273,"PHASE1":2275,"PHASE2":2277,"PHASE3":2279,"PHASE4":2290,"NA":2292},{"trials":2274,"activeCount":100},[],{"trials":2276,"activeCount":100},[],{"trials":2278,"activeCount":100},[],{"trials":2280,"activeCount":100},[2281],{"nctId":2282,"briefTitle":2283,"status":1109,"phases":2284,"primaryCompletion":2285,"completion":1135,"start":2286,"enrollment":2287,"conditions":2288,"interventions":2289},"NCT00265642","Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C",[90],"2013-04","2006-10",166,[1150],[2271],{"trials":2291,"activeCount":100},[],{"trials":2293,"activeCount":100},[],{"intervention":2295,"totalTrials":96,"cells":2296},"Pegylated interferon-alpha-2a",{"EARLY_PHASE1":2297,"PHASE1":2299,"PHASE2":2301,"PHASE3":2303,"PHASE4":2317,"NA":2319},{"trials":2298,"activeCount":100},[],{"trials":2300,"activeCount":100},[],{"trials":2302,"activeCount":100},[],{"trials":2304,"activeCount":100},[2305],{"nctId":2306,"briefTitle":2307,"status":193,"phases":2308,"primaryCompletion":2309,"completion":2309,"start":2310,"enrollment":2311,"conditions":2312,"interventions":2315},"NCT01172392","A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B",[90],"2015-06","2011-01",185,[2313,2314],"Chronic Hepatitis B","AgHbs Negativation",[2295,2316],"Nucleotidic or Nucleosidic Treatment",{"trials":2318,"activeCount":100},[],{"trials":2320,"activeCount":100},[],{"intervention":2316,"totalTrials":96,"cells":2322},{"EARLY_PHASE1":2323,"PHASE1":2325,"PHASE2":2327,"PHASE3":2329,"PHASE4":2335,"NA":2337},{"trials":2324,"activeCount":100},[],{"trials":2326,"activeCount":100},[],{"trials":2328,"activeCount":100},[],{"trials":2330,"activeCount":100},[2331],{"nctId":2306,"briefTitle":2307,"status":193,"phases":2332,"primaryCompletion":2309,"completion":2309,"start":2310,"enrollment":2311,"conditions":2333,"interventions":2334},[90],[2313,2314],[2295,2316],{"trials":2336,"activeCount":100},[],{"trials":2338,"activeCount":100},[],{"intervention":2340,"totalTrials":96,"cells":2341},"ARV bitherapie",{"EARLY_PHASE1":2342,"PHASE1":2344,"PHASE2":2346,"PHASE3":2348,"PHASE4":2360,"NA":2362},{"trials":2343,"activeCount":100},[],{"trials":2345,"activeCount":100},[],{"trials":2347,"activeCount":100},[],{"trials":2349,"activeCount":100},[2350],{"nctId":2351,"briefTitle":2352,"status":193,"phases":2353,"primaryCompletion":2354,"completion":2355,"start":2356,"enrollment":2357,"conditions":2358,"interventions":2359},"NCT04867083","Dual Therapy in HIV Patients in 4 Days a Week Versus 7 Days a Week",[90],"2023-07","2024-07","2021-06-21",440,[15],[2340],{"trials":2361,"activeCount":100},[],{"trials":2363,"activeCount":100},[],{"intervention":2365,"totalTrials":96,"cells":2366},"emtricitabine\u002Ftenofovir + lopinavir\u002Fritonavir",{"EARLY_PHASE1":2367,"PHASE1":2369,"PHASE2":2371,"PHASE3":2373,"PHASE4":2386,"NA":2388},{"trials":2368,"activeCount":100},[],{"trials":2370,"activeCount":100},[],{"trials":2372,"activeCount":100},[],{"trials":2374,"activeCount":100},[2375],{"nctId":2376,"briefTitle":2377,"status":1109,"phases":2378,"primaryCompletion":1146,"completion":2379,"start":2380,"enrollment":2381,"conditions":2382,"interventions":2383},"NCT00928187","Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)",[90],"2015-12","2009-11",454,[24,15],[2365,2384,2385],"abacavir + didanosine + lopinavir\u002Fritonavir","emtricitabine\u002Ftenofovir + darunavir + ritonavir",{"trials":2387,"activeCount":100},[],{"trials":2389,"activeCount":100},[],{"intervention":2384,"totalTrials":96,"cells":2391},{"EARLY_PHASE1":2392,"PHASE1":2394,"PHASE2":2396,"PHASE3":2398,"PHASE4":2404,"NA":2406},{"trials":2393,"activeCount":100},[],{"trials":2395,"activeCount":100},[],{"trials":2397,"activeCount":100},[],{"trials":2399,"activeCount":100},[2400],{"nctId":2376,"briefTitle":2377,"status":1109,"phases":2401,"primaryCompletion":1146,"completion":2379,"start":2380,"enrollment":2381,"conditions":2402,"interventions":2403},[90],[24,15],[2365,2384,2385],{"trials":2405,"activeCount":100},[],{"trials":2407,"activeCount":100},[],{"intervention":2385,"totalTrials":96,"cells":2409},{"EARLY_PHASE1":2410,"PHASE1":2412,"PHASE2":2414,"PHASE3":2416,"PHASE4":2422,"NA":2424},{"trials":2411,"activeCount":100},[],{"trials":2413,"activeCount":100},[],{"trials":2415,"activeCount":100},[],{"trials":2417,"activeCount":100},[2418],{"nctId":2376,"briefTitle":2377,"status":1109,"phases":2419,"primaryCompletion":1146,"completion":2379,"start":2380,"enrollment":2381,"conditions":2420,"interventions":2421},[90],[24,15],[2365,2384,2385],{"trials":2423,"activeCount":100},[],{"trials":2425,"activeCount":100},[],{"intervention":2427,"totalTrials":96,"cells":2428},"Nitazoxanide and Ciclésonide",{"EARLY_PHASE1":2429,"PHASE1":2431,"PHASE2":2433,"PHASE3":2435,"PHASE4":2452,"NA":2454},{"trials":2430,"activeCount":100},[],{"trials":2432,"activeCount":100},[],{"trials":2434,"activeCount":100},[],{"trials":2436,"activeCount":100},[2437],{"nctId":2438,"briefTitle":2439,"status":193,"phases":2440,"primaryCompletion":2441,"completion":2441,"start":2442,"enrollment":2443,"conditions":2444,"interventions":2448},"NCT04920838","Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection",[89,90],"2023-08","2021-04-12",600,[2445,2446,2226,2447],"Covid19","Covid19 Drug Treatment","SARS-CoV2 Infection",[2427,2449,2450,2451],"Telmisartan 20Mg Oral","Paracetamol","Fluoxétine and Budésonide",{"trials":2453,"activeCount":100},[],{"trials":2455,"activeCount":100},[],{"intervention":2449,"totalTrials":96,"cells":2457},{"EARLY_PHASE1":2458,"PHASE1":2460,"PHASE2":2462,"PHASE3":2464,"PHASE4":2470,"NA":2472},{"trials":2459,"activeCount":100},[],{"trials":2461,"activeCount":100},[],{"trials":2463,"activeCount":100},[],{"trials":2465,"activeCount":100},[2466],{"nctId":2438,"briefTitle":2439,"status":193,"phases":2467,"primaryCompletion":2441,"completion":2441,"start":2442,"enrollment":2443,"conditions":2468,"interventions":2469},[89,90],[2445,2446,2226,2447],[2427,2449,2450,2451],{"trials":2471,"activeCount":100},[],{"trials":2473,"activeCount":100},[],{"intervention":2450,"totalTrials":96,"cells":2475},{"EARLY_PHASE1":2476,"PHASE1":2478,"PHASE2":2480,"PHASE3":2482,"PHASE4":2488,"NA":2490},{"trials":2477,"activeCount":100},[],{"trials":2479,"activeCount":100},[],{"trials":2481,"activeCount":100},[],{"trials":2483,"activeCount":100},[2484],{"nctId":2438,"briefTitle":2439,"status":193,"phases":2485,"primaryCompletion":2441,"completion":2441,"start":2442,"enrollment":2443,"conditions":2486,"interventions":2487},[89,90],[2445,2446,2226,2447],[2427,2449,2450,2451],{"trials":2489,"activeCount":100},[],{"trials":2491,"activeCount":100},[],{"intervention":2451,"totalTrials":96,"cells":2493},{"EARLY_PHASE1":2494,"PHASE1":2496,"PHASE2":2498,"PHASE3":2500,"PHASE4":2506,"NA":2508},{"trials":2495,"activeCount":100},[],{"trials":2497,"activeCount":100},[],{"trials":2499,"activeCount":100},[],{"trials":2501,"activeCount":100},[2502],{"nctId":2438,"briefTitle":2439,"status":193,"phases":2503,"primaryCompletion":2441,"completion":2441,"start":2442,"enrollment":2443,"conditions":2504,"interventions":2505},[89,90],[2445,2446,2226,2447],[2427,2449,2450,2451],{"trials":2507,"activeCount":100},[],{"trials":2509,"activeCount":100},[],{"intervention":2511,"totalTrials":96,"cells":2512},"GenHevac B Pasteur",{"EARLY_PHASE1":2513,"PHASE1":2515,"PHASE2":2517,"PHASE3":2519,"PHASE4":2531,"NA":2533},{"trials":2514,"activeCount":100},[],{"trials":2516,"activeCount":100},[],{"trials":2518,"activeCount":100},[],{"trials":2520,"activeCount":100},[2521],{"nctId":2522,"briefTitle":2523,"status":1109,"phases":2524,"primaryCompletion":2525,"completion":2526,"start":2527,"enrollment":2528,"conditions":2529,"interventions":2530},"NCT00480792","Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients",[90],"2008-12","2012-09","2007-06",437,[15],[2511,2511,2511],{"trials":2532,"activeCount":100},[],{"trials":2534,"activeCount":100},[],{"intervention":2536,"totalTrials":96,"cells":2537},"Protease inhibitor",{"EARLY_PHASE1":2538,"PHASE1":2540,"PHASE2":2542,"PHASE3":2544,"PHASE4":2556,"NA":2558},{"trials":2539,"activeCount":100},[],{"trials":2541,"activeCount":100},[],{"trials":2543,"activeCount":100},[],{"trials":2545,"activeCount":100},[2546],{"nctId":2547,"briefTitle":2548,"status":2549,"phases":2550,"primaryCompletion":1747,"completion":1747,"start":2133,"enrollment":844,"conditions":2551,"interventions":2554},"NCT02247687","Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)","TERMINATED",[90],[21,2552,2553],"Treatment Resistant Disorders","Viremia",[2536,2555],"Isentress®",{"trials":2557,"activeCount":100},[],{"trials":2559,"activeCount":100},[],{"intervention":2555,"totalTrials":96,"cells":2561},{"EARLY_PHASE1":2562,"PHASE1":2564,"PHASE2":2566,"PHASE3":2568,"PHASE4":2574,"NA":2576},{"trials":2563,"activeCount":100},[],{"trials":2565,"activeCount":100},[],{"trials":2567,"activeCount":100},[],{"trials":2569,"activeCount":100},[2570],{"nctId":2547,"briefTitle":2548,"status":2549,"phases":2571,"primaryCompletion":1747,"completion":1747,"start":2133,"enrollment":844,"conditions":2572,"interventions":2573},[90],[21,2552,2553],[2536,2555],{"trials":2575,"activeCount":100},[],{"trials":2577,"activeCount":100},[],{"intervention":2579,"totalTrials":96,"cells":2580},"darunavir\u002Fritonavir QD + raltegravir BID",{"EARLY_PHASE1":2581,"PHASE1":2583,"PHASE2":2585,"PHASE3":2587,"PHASE4":2599,"NA":2601},{"trials":2582,"activeCount":100},[],{"trials":2584,"activeCount":100},[],{"trials":2586,"activeCount":100},[],{"trials":2588,"activeCount":100},[2589],{"nctId":2590,"briefTitle":2591,"status":1109,"phases":2592,"primaryCompletion":2593,"completion":2593,"start":2594,"enrollment":2595,"conditions":2596,"interventions":2597},"NCT01066962","Study of Darunavir\u002Fr + Tenofovir\u002FEmtricitabine vs. Darunavir\u002Fr + Raltegravir in HIV-infected Antiretroviral naïve Subjects",[90],"2013-10","2010-08",800,[15],[2579,2598],"darunavir\u002Fr QD + tenofovir\u002Femtricitabine QD",{"trials":2600,"activeCount":100},[],{"trials":2602,"activeCount":100},[],{"intervention":2598,"totalTrials":96,"cells":2604},{"EARLY_PHASE1":2605,"PHASE1":2607,"PHASE2":2609,"PHASE3":2611,"PHASE4":2617,"NA":2619},{"trials":2606,"activeCount":100},[],{"trials":2608,"activeCount":100},[],{"trials":2610,"activeCount":100},[],{"trials":2612,"activeCount":100},[2613],{"nctId":2590,"briefTitle":2591,"status":1109,"phases":2614,"primaryCompletion":2593,"completion":2593,"start":2594,"enrollment":2595,"conditions":2615,"interventions":2616},[90],[15],[2579,2598],{"trials":2618,"activeCount":100},[],{"trials":2620,"activeCount":100},[],{"intervention":2622,"totalTrials":96,"cells":2623},"Kaletra",{"EARLY_PHASE1":2624,"PHASE1":2626,"PHASE2":2628,"PHASE3":2630,"PHASE4":2641,"NA":2643},{"trials":2625,"activeCount":100},[],{"trials":2627,"activeCount":100},[],{"trials":2629,"activeCount":100},[],{"trials":2631,"activeCount":100},[2632],{"nctId":2633,"briefTitle":2634,"status":1109,"phases":2635,"primaryCompletion":1554,"completion":2636,"start":2637,"enrollment":2638,"conditions":2639,"interventions":2640},"NCT00424814","Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva",[89,90],"2012-11","2007-03",105,[15],[2622,2622],{"trials":2642,"activeCount":100},[],{"trials":2644,"activeCount":100},[],{"intervention":2646,"totalTrials":96,"cells":2647},"Tenofovir + Emtricitabine or Lamivudine + Zidovudine",{"EARLY_PHASE1":2648,"PHASE1":2650,"PHASE2":2652,"PHASE3":2654,"PHASE4":2668,"NA":2670},{"trials":2649,"activeCount":100},[],{"trials":2651,"activeCount":100},[],{"trials":2653,"activeCount":100},[],{"trials":2655,"activeCount":100},[2656],{"nctId":2657,"briefTitle":2658,"status":1109,"phases":2659,"primaryCompletion":2660,"completion":2660,"start":2661,"enrollment":2662,"conditions":2663,"interventions":2665},"NCT02150993","First-Line Treatment for HIV-2",[89,90],"2019-05-15","2016-01-26",210,[2664],"HIV-2 Infection",[2646,2666,2667],"Tenofovir + Emtricitabine or Lamivudine + Lopinavir\u002Fritonavir","Tenofovir + Emtricitabine or Lamivudine + Raltegravir",{"trials":2669,"activeCount":100},[],{"trials":2671,"activeCount":100},[],{"intervention":2666,"totalTrials":96,"cells":2673},{"EARLY_PHASE1":2674,"PHASE1":2676,"PHASE2":2678,"PHASE3":2680,"PHASE4":2686,"NA":2688},{"trials":2675,"activeCount":100},[],{"trials":2677,"activeCount":100},[],{"trials":2679,"activeCount":100},[],{"trials":2681,"activeCount":100},[2682],{"nctId":2657,"briefTitle":2658,"status":1109,"phases":2683,"primaryCompletion":2660,"completion":2660,"start":2661,"enrollment":2662,"conditions":2684,"interventions":2685},[89,90],[2664],[2646,2666,2667],{"trials":2687,"activeCount":100},[],{"trials":2689,"activeCount":100},[],{"intervention":2667,"totalTrials":96,"cells":2691},{"EARLY_PHASE1":2692,"PHASE1":2694,"PHASE2":2696,"PHASE3":2698,"PHASE4":2704,"NA":2706},{"trials":2693,"activeCount":100},[],{"trials":2695,"activeCount":100},[],{"trials":2697,"activeCount":100},[],{"trials":2699,"activeCount":100},[2700],{"nctId":2657,"briefTitle":2658,"status":1109,"phases":2701,"primaryCompletion":2660,"completion":2660,"start":2661,"enrollment":2662,"conditions":2702,"interventions":2703},[89,90],[2664],[2646,2666,2667],{"trials":2705,"activeCount":100},[],{"trials":2707,"activeCount":100},[],{"intervention":2709,"totalTrials":96,"cells":2710},"Truvada",{"EARLY_PHASE1":2711,"PHASE1":2713,"PHASE2":2715,"PHASE3":2717,"PHASE4":2729,"NA":2731},{"trials":2712,"activeCount":100},[],{"trials":2714,"activeCount":100},[],{"trials":2716,"activeCount":100},[],{"trials":2718,"activeCount":100},[2719],{"nctId":2720,"briefTitle":2721,"status":1109,"phases":2722,"primaryCompletion":2723,"completion":2724,"start":2725,"enrollment":2726,"conditions":2727,"interventions":2728},"NCT01473472","On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men",[90],"2016-06-30","2016-12-15","2012-01",400,[18],[2709],{"trials":2730,"activeCount":100},[],{"trials":2732,"activeCount":100},[],{"intervention":2734,"totalTrials":96,"cells":2735},"Four consecutive days on treatment and 3 days off",{"EARLY_PHASE1":2736,"PHASE1":2738,"PHASE2":2740,"PHASE3":2742,"PHASE4":2751,"NA":2753},{"trials":2737,"activeCount":100},[],{"trials":2739,"activeCount":100},[],{"trials":2741,"activeCount":100},[],{"trials":2743,"activeCount":100},[2744],{"nctId":2745,"briefTitle":2746,"status":1109,"phases":2747,"primaryCompletion":1113,"completion":1113,"start":1864,"enrollment":2748,"conditions":2749,"interventions":2750},"NCT02157311","4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients",[90],100,[21],[2734],{"trials":2752,"activeCount":100},[],{"trials":2754,"activeCount":100},[],{"intervention":1117,"totalTrials":229,"cells":2756},{"EARLY_PHASE1":2757,"PHASE1":2759,"PHASE2":2761,"PHASE3":2771,"PHASE4":2773,"NA":2775},{"trials":2758,"activeCount":100},[],{"trials":2760,"activeCount":100},[],{"trials":2762,"activeCount":100},[2763,2767],{"nctId":1107,"briefTitle":1108,"status":1109,"phases":2764,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":19,"conditions":2765,"interventions":2766},[89],[32],[1116,1117,1097],{"nctId":1119,"briefTitle":1120,"status":1109,"phases":2768,"primaryCompletion":1122,"completion":1123,"start":1124,"enrollment":1125,"conditions":2769,"interventions":2770},[89],[32,18],[1117,1097,1117,1128],{"trials":2772,"activeCount":100},[],{"trials":2774,"activeCount":100},[],{"trials":2776,"activeCount":100},[],{"intervention":2778,"totalTrials":96,"cells":2779},"Dolutegravir + Darunavir\u002Fritonavir + optimized NRTI",{"EARLY_PHASE1":2780,"PHASE1":2782,"PHASE2":2784,"PHASE3":2795,"PHASE4":2797,"NA":2799},{"trials":2781,"activeCount":100},[],{"trials":2783,"activeCount":100},[],{"trials":2785,"activeCount":100},[2786],{"nctId":2787,"briefTitle":2788,"status":193,"phases":2789,"primaryCompletion":2790,"completion":2790,"start":2791,"enrollment":2792,"conditions":2793,"interventions":2794},"NCT03602690","Evaluation of Third-line cART Regimen in Cambodia (3DICAM)",[89],"2022-04-11","2018-10-04",54,[268],[2778],{"trials":2796,"activeCount":100},[],{"trials":2798,"activeCount":100},[],{"trials":2800,"activeCount":100},[],{"intervention":2802,"totalTrials":96,"cells":2803},"Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a",{"EARLY_PHASE1":2804,"PHASE1":2806,"PHASE2":2808,"PHASE3":2820,"PHASE4":2822,"NA":2824},{"trials":2805,"activeCount":100},[],{"trials":2807,"activeCount":100},[],{"trials":2809,"activeCount":100},[2810],{"nctId":2811,"briefTitle":2812,"status":1109,"phases":2813,"primaryCompletion":2084,"completion":2814,"start":2815,"enrollment":2816,"conditions":2817,"interventions":2819},"NCT01725542","Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders",[89],"2014-06","2012-12",75,[2818],"HCV-HIV Co-Infection",[2802],{"trials":2821,"activeCount":100},[],{"trials":2823,"activeCount":100},[],{"trials":2825,"activeCount":100},[],{"intervention":1116,"totalTrials":96,"cells":2827},{"EARLY_PHASE1":2828,"PHASE1":2830,"PHASE2":2832,"PHASE3":2838,"PHASE4":2840,"NA":2842},{"trials":2829,"activeCount":100},[],{"trials":2831,"activeCount":100},[],{"trials":2833,"activeCount":100},[2834],{"nctId":1107,"briefTitle":1108,"status":1109,"phases":2835,"primaryCompletion":1111,"completion":1112,"start":1113,"enrollment":19,"conditions":2836,"interventions":2837},[89],[32],[1116,1117,1097],{"trials":2839,"activeCount":100},[],{"trials":2841,"activeCount":100},[],{"trials":2843,"activeCount":100},[],{"intervention":2845,"totalTrials":96,"cells":2846},"administration of SLGN in arm C",{"EARLY_PHASE1":2847,"PHASE1":2849,"PHASE2":2851,"PHASE3":2863,"PHASE4":2865,"NA":2867},{"trials":2848,"activeCount":100},[],{"trials":2850,"activeCount":100},[],{"trials":2852,"activeCount":100},[2853],{"nctId":2854,"briefTitle":2855,"status":193,"phases":2856,"primaryCompletion":2857,"completion":2857,"start":2858,"enrollment":2748,"conditions":2859,"interventions":2861},"NCT05045261","ANRS HB07 IP-Cure-B Proof of Concept (PoC) Clinical Trial. Educating the Liver Immune Environment Through TLR8 Stimulation Followed by NUC Discontinuation",[89],"2024-06-30","2022-02-01",[2860],"Hepatitis B, Chronic",[2845,2862],"Discontinuation of NUC treatment in arms B and C",{"trials":2864,"activeCount":100},[],{"trials":2866,"activeCount":100},[],{"trials":2868,"activeCount":100},[],{"intervention":2862,"totalTrials":96,"cells":2870},{"EARLY_PHASE1":2871,"PHASE1":2873,"PHASE2":2875,"PHASE3":2881,"PHASE4":2883,"NA":2885},{"trials":2872,"activeCount":100},[],{"trials":2874,"activeCount":100},[],{"trials":2876,"activeCount":100},[2877],{"nctId":2854,"briefTitle":2855,"status":193,"phases":2878,"primaryCompletion":2857,"completion":2857,"start":2858,"enrollment":2748,"conditions":2879,"interventions":2880},[89],[2860],[2845,2862],{"trials":2882,"activeCount":100},[],{"trials":2884,"activeCount":100},[],{"trials":2886,"activeCount":100},[],{"intervention":2888,"totalTrials":96,"cells":2889},"BBIBP-CorV",{"EARLY_PHASE1":2890,"PHASE1":2892,"PHASE2":2894,"PHASE3":2909,"PHASE4":2911,"NA":2913},{"trials":2891,"activeCount":100},[],{"trials":2893,"activeCount":100},[],{"trials":2895,"activeCount":100},[2896],{"nctId":2897,"briefTitle":2898,"status":193,"phases":2899,"primaryCompletion":2900,"completion":2901,"start":2902,"enrollment":2903,"conditions":2904,"interventions":2908},"NCT05409300","Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea",[89],"2023-08-03","2025-02","2022-04-25",200,[35,2905,2906,2907],"Vaccine Adverse Reaction","Sars-CoV-2 Infection","Healthy Volunteer",[2888],{"trials":2910,"activeCount":100},[],{"trials":2912,"activeCount":100},[],{"trials":2914,"activeCount":100},[],{"intervention":2916,"totalTrials":96,"cells":2917},"Boceprevir, Peg-interferon alfa 2b and Ribavirin",{"EARLY_PHASE1":2918,"PHASE1":2920,"PHASE2":2922,"PHASE3":2933,"PHASE4":2935,"NA":2937},{"trials":2919,"activeCount":100},[],{"trials":2921,"activeCount":100},[],{"trials":2923,"activeCount":100},[2924],{"nctId":2925,"briefTitle":2926,"status":1109,"phases":2927,"primaryCompletion":2928,"completion":2928,"start":2929,"enrollment":542,"conditions":2930,"interventions":2932},"NCT01335529","Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon\u002FRibavirin",[89],"2014-05","2011-05",[2931,21],"HCV Coinfection",[2916],{"trials":2934,"activeCount":100},[],{"trials":2936,"activeCount":100},[],{"trials":2938,"activeCount":100},[],{"intervention":2940,"totalTrials":96,"cells":2941},"LIPO-5",{"EARLY_PHASE1":2942,"PHASE1":2944,"PHASE2":2946,"PHASE3":2958,"PHASE4":2960,"NA":2962},{"trials":2943,"activeCount":100},[],{"trials":2945,"activeCount":100},[],{"trials":2947,"activeCount":100},[2948],{"nctId":2949,"briefTitle":2950,"status":1109,"phases":2951,"primaryCompletion":1124,"completion":1553,"start":2952,"enrollment":2953,"conditions":2954,"interventions":2955},"NCT02038842","Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers",[88,89],"2014-03",92,[18],[2940,2956,2957],"MVA HIV-B","GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots",{"trials":2959,"activeCount":100},[],{"trials":2961,"activeCount":100},[],{"trials":2963,"activeCount":100},[],{"intervention":2956,"totalTrials":96,"cells":2965},{"EARLY_PHASE1":2966,"PHASE1":2968,"PHASE2":2970,"PHASE3":2976,"PHASE4":2978,"NA":2980},{"trials":2967,"activeCount":100},[],{"trials":2969,"activeCount":100},[],{"trials":2971,"activeCount":100},[2972],{"nctId":2949,"briefTitle":2950,"status":1109,"phases":2973,"primaryCompletion":1124,"completion":1553,"start":2952,"enrollment":2953,"conditions":2974,"interventions":2975},[88,89],[18],[2940,2956,2957],{"trials":2977,"activeCount":100},[],{"trials":2979,"activeCount":100},[],{"trials":2981,"activeCount":100},[],{"intervention":2957,"totalTrials":96,"cells":2983},{"EARLY_PHASE1":2984,"PHASE1":2986,"PHASE2":2988,"PHASE3":2994,"PHASE4":2996,"NA":2998},{"trials":2985,"activeCount":100},[],{"trials":2987,"activeCount":100},[],{"trials":2989,"activeCount":100},[2990],{"nctId":2949,"briefTitle":2950,"status":1109,"phases":2991,"primaryCompletion":1124,"completion":1553,"start":2952,"enrollment":2953,"conditions":2992,"interventions":2993},[88,89],[18],[2940,2956,2957],{"trials":2995,"activeCount":100},[],{"trials":2997,"activeCount":100},[],{"trials":2999,"activeCount":100},[],{"intervention":3001,"totalTrials":96,"cells":3002},"Vaccine and vedolizumab",{"EARLY_PHASE1":3003,"PHASE1":3005,"PHASE2":3007,"PHASE3":3017,"PHASE4":3019,"NA":3021},{"trials":3004,"activeCount":100},[],{"trials":3006,"activeCount":100},[],{"trials":3008,"activeCount":100},[3009],{"nctId":3010,"briefTitle":3011,"status":1109,"phases":3012,"primaryCompletion":3013,"completion":3013,"start":3014,"enrollment":229,"conditions":3015,"interventions":3016},"NCT04120415","A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02)",[89],"2023-07-12","2022-06-21",[30],[3001],{"trials":3018,"activeCount":100},[],{"trials":3020,"activeCount":100},[],{"trials":3022,"activeCount":100},[],{"intervention":3024,"totalTrials":96,"cells":3025},".Asunaprevir, Daclatasvir and BMS - 791325",{"EARLY_PHASE1":3026,"PHASE1":3028,"PHASE2":3030,"PHASE3":3039,"PHASE4":3041,"NA":3043},{"trials":3027,"activeCount":100},[],{"trials":3029,"activeCount":100},[],{"trials":3031,"activeCount":100},[3032],{"nctId":3033,"briefTitle":3034,"status":2082,"phases":3035,"primaryCompletion":1461,"completion":3036,"start":2133,"enrollment":100,"conditions":3037,"interventions":3038},"NCT02309450","Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen",[89],"2016-08",[1137],[3024],{"trials":3040,"activeCount":100},[],{"trials":3042,"activeCount":100},[],{"trials":3044,"activeCount":100},[],{"intervention":1128,"totalTrials":96,"cells":3046},{"EARLY_PHASE1":3047,"PHASE1":3049,"PHASE2":3051,"PHASE3":3057,"PHASE4":3059,"NA":3061},{"trials":3048,"activeCount":100},[],{"trials":3050,"activeCount":100},[],{"trials":3052,"activeCount":100},[3053],{"nctId":1119,"briefTitle":1120,"status":1109,"phases":3054,"primaryCompletion":1122,"completion":1123,"start":1124,"enrollment":1125,"conditions":3055,"interventions":3056},[89],[32,18],[1117,1097,1117,1128],{"trials":3058,"activeCount":100},[],{"trials":3060,"activeCount":100},[],{"trials":3062,"activeCount":100},[],{"intervention":3064,"totalTrials":96,"cells":3065},"Raltegravir potassium",{"EARLY_PHASE1":3066,"PHASE1":3068,"PHASE2":3070,"PHASE3":3081,"PHASE4":3083,"NA":3085},{"trials":3067,"activeCount":100},[],{"trials":3069,"activeCount":100},[],{"trials":3071,"activeCount":100},[3072],{"nctId":3073,"briefTitle":3074,"status":1109,"phases":3075,"primaryCompletion":2132,"completion":2132,"start":3076,"enrollment":25,"conditions":3077,"interventions":3080},"NCT01022476","Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients",[88,89],"2010-05",[18,3078,3079],"Liver Failure","Evidence of Liver Transplantation",[3064],{"trials":3082,"activeCount":100},[],{"trials":3084,"activeCount":100},[],{"trials":3086,"activeCount":100},[],{"intervention":3088,"totalTrials":96,"cells":3089},"Antiretroviral Therapy Darunavir\u002Fr + Raltegravir + 2 NRTIs",{"EARLY_PHASE1":3090,"PHASE1":3092,"PHASE2":3094,"PHASE3":3104,"PHASE4":3106,"NA":3108},{"trials":3091,"activeCount":100},[],{"trials":3093,"activeCount":100},[],{"trials":3095,"activeCount":100},[3096],{"nctId":3097,"briefTitle":3098,"status":193,"phases":3099,"primaryCompletion":3036,"completion":3100,"start":1161,"enrollment":3101,"conditions":3102,"interventions":3103},"NCT02025868","Third Line Antiretroviral Treatment Optimization in Sub-Saharan Africa",[89],"2017-05",201,[18],[3088],{"trials":3105,"activeCount":100},[],{"trials":3107,"activeCount":100},[],{"trials":3109,"activeCount":100},[],{"intervention":201,"totalTrials":96,"cells":3111},{"EARLY_PHASE1":3112,"PHASE1":3114,"PHASE2":3116,"PHASE3":3122,"PHASE4":3124,"NA":3126},{"trials":3113,"activeCount":100},[],{"trials":3115,"activeCount":100},[],{"trials":3117,"activeCount":100},[3118],{"nctId":191,"briefTitle":192,"status":193,"phases":3119,"primaryCompletion":195,"completion":195,"start":196,"enrollment":197,"conditions":3120,"interventions":3121},[89],[199],[201,181],{"trials":3123,"activeCount":100},[],{"trials":3125,"activeCount":100},[],{"trials":3127,"activeCount":100},[],{"intervention":3129,"totalTrials":96,"cells":3130},"Methylphenidate Pill",{"EARLY_PHASE1":3131,"PHASE1":3133,"PHASE2":3135,"PHASE3":3147,"PHASE4":3149,"NA":3151},{"trials":3132,"activeCount":100},[],{"trials":3134,"activeCount":100},[],{"trials":3136,"activeCount":100},[3137],{"nctId":3138,"briefTitle":3139,"status":2082,"phases":3140,"primaryCompletion":3141,"completion":3142,"start":3143,"enrollment":100,"conditions":3144,"interventions":3146},"NCT03090269","Methylphenidate for Cocaine Dependence",[89],"2018-12-31","2019-03-30","2018-06-01",[3145],"Substance-Related Disorders",[3129],{"trials":3148,"activeCount":100},[],{"trials":3150,"activeCount":100},[],{"trials":3152,"activeCount":100},[],{"intervention":3154,"totalTrials":96,"cells":3155},"raltegravir and etravirine",{"EARLY_PHASE1":3156,"PHASE1":3158,"PHASE2":3160,"PHASE3":3171,"PHASE4":3173,"NA":3175},{"trials":3157,"activeCount":100},[],{"trials":3159,"activeCount":100},[],{"trials":3161,"activeCount":100},[3162],{"nctId":3163,"briefTitle":3164,"status":1109,"phases":3165,"primaryCompletion":3166,"completion":1284,"start":3167,"enrollment":3168,"conditions":3169,"interventions":3170},"NCT02212379","Capacity of the Dual Combination Raltegravir\u002FEtravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL",[89],"2017-10","2015-01",170,[21],[3154],{"trials":3172,"activeCount":100},[],{"trials":3174,"activeCount":100},[],{"trials":3176,"activeCount":100},[],{"intervention":3178,"totalTrials":96,"cells":3179},"Raltegravir-Maraviroc",{"EARLY_PHASE1":3180,"PHASE1":3182,"PHASE2":3184,"PHASE3":3194,"PHASE4":3196,"NA":3198},{"trials":3181,"activeCount":100},[],{"trials":3183,"activeCount":100},[],{"trials":3185,"activeCount":100},[3186],{"nctId":3187,"briefTitle":3188,"status":2549,"phases":3189,"primaryCompletion":2285,"completion":2285,"start":1462,"enrollment":459,"conditions":3190,"interventions":3193},"NCT01420523","Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy",[89],[3191,3192],"Human Immunodeficiency Virus","Lipohypertrophy",[3178],{"trials":3195,"activeCount":100},[],{"trials":3197,"activeCount":100},[],{"trials":3199,"activeCount":100},[],{"intervention":3201,"totalTrials":96,"cells":3202},"GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine",{"EARLY_PHASE1":3203,"PHASE1":3205,"PHASE2":3207,"PHASE3":3219,"PHASE4":3221,"NA":3223},{"trials":3204,"activeCount":100},[],{"trials":3206,"activeCount":100},[],{"trials":3208,"activeCount":100},[3209],{"nctId":3210,"briefTitle":3211,"status":2549,"phases":3212,"primaryCompletion":3213,"completion":3213,"start":3214,"enrollment":96,"conditions":3215,"interventions":3216},"NCT02972450","An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic Infection",[88,89],"2019-07-11","2019-02-20",[30],[3201,3217,3218],"GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine+ Vedolizumab","Vedolizumab 300 MG [Entyvio]",{"trials":3220,"activeCount":100},[],{"trials":3222,"activeCount":100},[],{"trials":3224,"activeCount":100},[],{"intervention":3217,"totalTrials":96,"cells":3226},{"EARLY_PHASE1":3227,"PHASE1":3229,"PHASE2":3231,"PHASE3":3237,"PHASE4":3239,"NA":3241},{"trials":3228,"activeCount":100},[],{"trials":3230,"activeCount":100},[],{"trials":3232,"activeCount":100},[3233],{"nctId":3210,"briefTitle":3211,"status":2549,"phases":3234,"primaryCompletion":3213,"completion":3213,"start":3214,"enrollment":96,"conditions":3235,"interventions":3236},[88,89],[30],[3201,3217,3218],{"trials":3238,"activeCount":100},[],{"trials":3240,"activeCount":100},[],{"trials":3242,"activeCount":100},[],{"intervention":3218,"totalTrials":96,"cells":3244},{"EARLY_PHASE1":3245,"PHASE1":3247,"PHASE2":3249,"PHASE3":3255,"PHASE4":3257,"NA":3259},{"trials":3246,"activeCount":100},[],{"trials":3248,"activeCount":100},[],{"trials":3250,"activeCount":100},[3251],{"nctId":3210,"briefTitle":3211,"status":2549,"phases":3252,"primaryCompletion":3213,"completion":3213,"start":3214,"enrollment":96,"conditions":3253,"interventions":3254},[88,89],[30],[3201,3217,3218],{"trials":3256,"activeCount":100},[],{"trials":3258,"activeCount":100},[],{"trials":3260,"activeCount":100},[],{"intervention":3262,"totalTrials":96,"cells":3263},"Structured treatment interruption",{"EARLY_PHASE1":3264,"PHASE1":3266,"PHASE2":3268,"PHASE3":3277,"PHASE4":3279,"NA":3281},{"trials":3265,"activeCount":100},[],{"trials":3267,"activeCount":100},[],{"trials":3269,"activeCount":100},[3270],{"nctId":3271,"briefTitle":3272,"status":1109,"phases":3273,"primaryCompletion":1449,"completion":1449,"start":3274,"enrollment":11,"conditions":3275,"interventions":3276},"NCT00820118","Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults",[89],"2009-05",[15],[3262],{"trials":3278,"activeCount":100},[],{"trials":3280,"activeCount":100},[],{"trials":3282,"activeCount":100},[],{"intervention":3284,"totalTrials":96,"cells":3285},"Peg-interféron alpha 2a + ribavirin",{"EARLY_PHASE1":3286,"PHASE1":3288,"PHASE2":3290,"PHASE3":3302,"PHASE4":3304,"NA":3306},{"trials":3287,"activeCount":100},[],{"trials":3289,"activeCount":100},[],{"trials":3291,"activeCount":100},[3292],{"nctId":3293,"briefTitle":3294,"status":1109,"phases":3295,"primaryCompletion":3296,"completion":3296,"start":3297,"enrollment":3298,"conditions":3299,"interventions":3301},"NCT00901524","ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV",[89],"2012-06","2009-06",58,[3300],"Hepatitis",[3284],{"trials":3303,"activeCount":100},[],{"trials":3305,"activeCount":100},[],{"trials":3307,"activeCount":100},[],{"intervention":3309,"totalTrials":96,"cells":3310},"drug administration",{"EARLY_PHASE1":3311,"PHASE1":3313,"PHASE2":3315,"PHASE3":3324,"PHASE4":3326,"NA":3328},{"trials":3312,"activeCount":100},[],{"trials":3314,"activeCount":100},[],{"trials":3316,"activeCount":100},[3317],{"nctId":3318,"briefTitle":3319,"status":193,"phases":3320,"primaryCompletion":3321,"completion":3321,"start":2039,"enrollment":2638,"conditions":3322,"interventions":3323},"NCT01986543","Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection",[89],"2017-12",[27,24],[3309],{"trials":3325,"activeCount":100},[],{"trials":3327,"activeCount":100},[],{"trials":3329,"activeCount":100},[],{"intervention":3331,"totalTrials":96,"cells":3332},"Sofosbuvir\u002FLedipasvir fixed dose",{"EARLY_PHASE1":3333,"PHASE1":3335,"PHASE2":3337,"PHASE3":3347,"PHASE4":3349,"NA":3351},{"trials":3334,"activeCount":100},[],{"trials":3336,"activeCount":100},[],{"trials":3338,"activeCount":100},[3339],{"nctId":3340,"briefTitle":3341,"status":1109,"phases":3342,"primaryCompletion":2379,"completion":2379,"start":3343,"enrollment":3344,"conditions":3345,"interventions":3346},"NCT02125500","Pilot Study to Assess Efficacy and Safety of Sofosbuvir\u002FLedipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection",[89],"2014-08",68,[1181,24],[3331],{"trials":3348,"activeCount":100},[],{"trials":3350,"activeCount":100},[],{"trials":3352,"activeCount":100},[],{"intervention":3354,"totalTrials":96,"cells":3355},"Ad26.COV2.S",{"EARLY_PHASE1":3356,"PHASE1":3358,"PHASE2":3360,"PHASE3":3373,"PHASE4":3375,"NA":3377},{"trials":3357,"activeCount":100},[],{"trials":3359,"activeCount":100},[],{"trials":3361,"activeCount":100},[3362],{"nctId":3363,"briefTitle":3364,"status":193,"phases":3365,"primaryCompletion":3366,"completion":3367,"start":3368,"enrollment":2903,"conditions":3369,"interventions":3372},"NCT05409261","Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine",[89],"2022-09-25","2025-03","2022-06-02",[35,3370,3371,2905],"Vaccine Reaction","SARS CoV 2 Infection",[3354],{"trials":3374,"activeCount":100},[],{"trials":3376,"activeCount":100},[],{"trials":3378,"activeCount":100},[],{"intervention":1454,"totalTrials":96,"cells":3380},{"EARLY_PHASE1":3381,"PHASE1":3383,"PHASE2":3385,"PHASE3":3391,"PHASE4":3393,"NA":3395},{"trials":3382,"activeCount":100},[],{"trials":3384,"activeCount":100},[],{"trials":3386,"activeCount":100},[3387],{"nctId":1445,"briefTitle":1446,"status":1109,"phases":3388,"primaryCompletion":1448,"completion":1449,"start":1450,"enrollment":1451,"conditions":3389,"interventions":3390},[89],[15,27],[1454,1436,1436],{"trials":3392,"activeCount":100},[],{"trials":3394,"activeCount":100},[],{"trials":3396,"activeCount":100},[],{"intervention":3398,"totalTrials":96,"cells":3399},"emtricitabine \u002F tenofovir disoproxil fumarate \u002F raltegravir .",{"EARLY_PHASE1":3400,"PHASE1":3402,"PHASE2":3404,"PHASE3":3414,"PHASE4":3416,"NA":3418},{"trials":3401,"activeCount":100},[],{"trials":3403,"activeCount":100},[],{"trials":3405,"activeCount":100},[3406],{"nctId":3407,"briefTitle":3408,"status":1109,"phases":3409,"primaryCompletion":2379,"completion":2379,"start":3410,"enrollment":3411,"conditions":3412,"interventions":3413},"NCT01605890","Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients",[89],"2012-07",30,[2664],[3398],{"trials":3415,"activeCount":100},[],{"trials":3417,"activeCount":100},[],{"trials":3419,"activeCount":100},[],{"intervention":3421,"totalTrials":96,"cells":3422},"Darunavir",{"EARLY_PHASE1":3423,"PHASE1":3425,"PHASE2":3427,"PHASE3":3438,"PHASE4":3440,"NA":3442},{"trials":3424,"activeCount":100},[],{"trials":3426,"activeCount":100},[],{"trials":3428,"activeCount":100},[3429],{"nctId":3430,"briefTitle":3431,"status":1109,"phases":3432,"primaryCompletion":3433,"completion":3433,"start":3434,"enrollment":2748,"conditions":3435,"interventions":3437},"NCT02384967","Evaluation of a Dose Reduction of Darunavir (400 mg\u002Fd) in Virologically Suppressed HIV-1 Patients",[89],"2016-10","2015-03",[3436],"HIV INFECTION",[3421],{"trials":3439,"activeCount":100},[],{"trials":3441,"activeCount":100},[],{"trials":3443,"activeCount":100},[],{"intervention":3445,"totalTrials":96,"cells":3446},"IFN alfa-2b XL 27 MUI + Ribavirin",{"EARLY_PHASE1":3447,"PHASE1":3449,"PHASE2":3451,"PHASE3":3463,"PHASE4":3465,"NA":3467},{"trials":3448,"activeCount":100},[],{"trials":3450,"activeCount":100},[],{"trials":3452,"activeCount":100},[3453],{"nctId":3454,"briefTitle":3455,"status":193,"phases":3456,"primaryCompletion":2526,"completion":1135,"start":3457,"enrollment":3458,"conditions":3459,"interventions":3460},"NCT01010646","Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4",[89],"2010-03",84,[2086],[3445,3461,3462],"IFN alfa-2b XL 36 MUI + Ribavirin","IFN peg alfa-2b 1.5 µg\u002Fkg + Ribavirin",{"trials":3464,"activeCount":100},[],{"trials":3466,"activeCount":100},[],{"trials":3468,"activeCount":100},[],{"intervention":3461,"totalTrials":96,"cells":3470},{"EARLY_PHASE1":3471,"PHASE1":3473,"PHASE2":3475,"PHASE3":3481,"PHASE4":3483,"NA":3485},{"trials":3472,"activeCount":100},[],{"trials":3474,"activeCount":100},[],{"trials":3476,"activeCount":100},[3477],{"nctId":3454,"briefTitle":3455,"status":193,"phases":3478,"primaryCompletion":2526,"completion":1135,"start":3457,"enrollment":3458,"conditions":3479,"interventions":3480},[89],[2086],[3445,3461,3462],{"trials":3482,"activeCount":100},[],{"trials":3484,"activeCount":100},[],{"trials":3486,"activeCount":100},[],{"intervention":3462,"totalTrials":96,"cells":3488},{"EARLY_PHASE1":3489,"PHASE1":3491,"PHASE2":3493,"PHASE3":3499,"PHASE4":3501,"NA":3503},{"trials":3490,"activeCount":100},[],{"trials":3492,"activeCount":100},[],{"trials":3494,"activeCount":100},[3495],{"nctId":3454,"briefTitle":3455,"status":193,"phases":3496,"primaryCompletion":2526,"completion":1135,"start":3457,"enrollment":3458,"conditions":3497,"interventions":3498},[89],[2086],[3445,3461,3462],{"trials":3500,"activeCount":100},[],{"trials":3502,"activeCount":100},[],{"trials":3504,"activeCount":100},[],{"intervention":3506,"totalTrials":96,"cells":3507},"Placebos of GTU-multiHIV B and LIPO-5 vaccines",{"EARLY_PHASE1":3508,"PHASE1":3510,"PHASE2":3512,"PHASE3":3523,"PHASE4":3525,"NA":3527},{"trials":3509,"activeCount":100},[],{"trials":3511,"activeCount":100},[],{"trials":3513,"activeCount":100},[3514],{"nctId":3515,"briefTitle":3516,"status":1109,"phases":3517,"primaryCompletion":3433,"completion":3518,"start":2038,"enrollment":3519,"conditions":3520,"interventions":3521},"NCT01492985","Lipopeptide Immunisation With GTU-multiHIV Trial",[89],"2017-04-08",103,[21],[3506,3522],"GTU-multHIV B vaccine and LIPO-5 vaccine",{"trials":3524,"activeCount":100},[],{"trials":3526,"activeCount":100},[],{"trials":3528,"activeCount":100},[],{"intervention":3522,"totalTrials":96,"cells":3530},{"EARLY_PHASE1":3531,"PHASE1":3533,"PHASE2":3535,"PHASE3":3541,"PHASE4":3543,"NA":3545},{"trials":3532,"activeCount":100},[],{"trials":3534,"activeCount":100},[],{"trials":3536,"activeCount":100},[3537],{"nctId":3515,"briefTitle":3516,"status":1109,"phases":3538,"primaryCompletion":3433,"completion":3518,"start":2038,"enrollment":3519,"conditions":3539,"interventions":3540},[89],[21],[3506,3522],{"trials":3542,"activeCount":100},[],{"trials":3544,"activeCount":100},[],{"trials":3546,"activeCount":100},[],{"intervention":3548,"totalTrials":96,"cells":3549},"3 doses of BNT162b2 vaccine",{"EARLY_PHASE1":3550,"PHASE1":3552,"PHASE2":3554,"PHASE3":3568,"PHASE4":3570,"NA":3572},{"trials":3551,"activeCount":100},[],{"trials":3553,"activeCount":100},[],{"trials":3555,"activeCount":100},[3556],{"nctId":3557,"briefTitle":3558,"status":1109,"phases":3559,"primaryCompletion":3560,"completion":3561,"start":3562,"enrollment":3563,"conditions":3564,"interventions":3566},"NCT04824638","BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers",[89],"2021-06-30","2023-12-02","2021-03-08",267,[626,3565],"Immunization; Infection",[3548,3567],"2 dose of BNT162b2 vaccine",{"trials":3569,"activeCount":100},[],{"trials":3571,"activeCount":100},[],{"trials":3573,"activeCount":100},[],{"intervention":3567,"totalTrials":96,"cells":3575},{"EARLY_PHASE1":3576,"PHASE1":3578,"PHASE2":3580,"PHASE3":3586,"PHASE4":3588,"NA":3590},{"trials":3577,"activeCount":100},[],{"trials":3579,"activeCount":100},[],{"trials":3581,"activeCount":100},[3582],{"nctId":3557,"briefTitle":3558,"status":1109,"phases":3583,"primaryCompletion":3560,"completion":3561,"start":3562,"enrollment":3563,"conditions":3584,"interventions":3585},[89],[626,3565],[3548,3567],{"trials":3587,"activeCount":100},[],{"trials":3589,"activeCount":100},[],{"trials":3591,"activeCount":100},[],{"intervention":1139,"totalTrials":96,"cells":3593},{"EARLY_PHASE1":3594,"PHASE1":3596,"PHASE2":3598,"PHASE3":3604,"PHASE4":3606,"NA":3608},{"trials":3595,"activeCount":100},[],{"trials":3597,"activeCount":100},[],{"trials":3599,"activeCount":100},[3600],{"nctId":1130,"briefTitle":1131,"status":1109,"phases":3601,"primaryCompletion":1133,"completion":1134,"start":1135,"enrollment":1028,"conditions":3602,"interventions":3603},[89],[1137],[1139,1140,1097,1141],{"trials":3605,"activeCount":100},[],{"trials":3607,"activeCount":100},[],{"trials":3609,"activeCount":100},[],{"intervention":1140,"totalTrials":96,"cells":3611},{"EARLY_PHASE1":3612,"PHASE1":3614,"PHASE2":3616,"PHASE3":3622,"PHASE4":3624,"NA":3626},{"trials":3613,"activeCount":100},[],{"trials":3615,"activeCount":100},[],{"trials":3617,"activeCount":100},[3618],{"nctId":1130,"briefTitle":1131,"status":1109,"phases":3619,"primaryCompletion":1133,"completion":1134,"start":1135,"enrollment":1028,"conditions":3620,"interventions":3621},[89],[1137],[1139,1140,1097,1141],{"trials":3623,"activeCount":100},[],{"trials":3625,"activeCount":100},[],{"trials":3627,"activeCount":100},[],{"intervention":1141,"totalTrials":96,"cells":3629},{"EARLY_PHASE1":3630,"PHASE1":3632,"PHASE2":3634,"PHASE3":3640,"PHASE4":3642,"NA":3644},{"trials":3631,"activeCount":100},[],{"trials":3633,"activeCount":100},[],{"trials":3635,"activeCount":100},[3636],{"nctId":1130,"briefTitle":1131,"status":1109,"phases":3637,"primaryCompletion":1133,"completion":1134,"start":1135,"enrollment":1028,"conditions":3638,"interventions":3639},[89],[1137],[1139,1140,1097,1141],{"trials":3641,"activeCount":100},[],{"trials":3643,"activeCount":100},[],{"trials":3645,"activeCount":100},[],{"intervention":3647,"totalTrials":96,"cells":3648},"darunavir monotherapy",{"EARLY_PHASE1":3649,"PHASE1":3651,"PHASE2":3653,"PHASE3":3666,"PHASE4":3668,"NA":3670},{"trials":3650,"activeCount":100},[],{"trials":3652,"activeCount":100},[],{"trials":3654,"activeCount":100},[3655],{"nctId":3656,"briefTitle":3657,"status":1109,"phases":3658,"primaryCompletion":3659,"completion":3660,"start":3661,"enrollment":3662,"conditions":3663,"interventions":3665},"NCT02738502","Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors",[89],"2019-07-16","2020-07-16","2016-07-06",91,[3664],"Maternal-fetal Infection Transmission",[3647],{"trials":3667,"activeCount":100},[],{"trials":3669,"activeCount":100},[],{"trials":3671,"activeCount":100},[],{"intervention":3673,"totalTrials":96,"cells":3674},"DNA-C",{"EARLY_PHASE1":3675,"PHASE1":3677,"PHASE2":3679,"PHASE3":3690,"PHASE4":3692,"NA":3694},{"trials":3676,"activeCount":100},[],{"trials":3678,"activeCount":100},[],{"trials":3680,"activeCount":100},[3681],{"nctId":3682,"briefTitle":3683,"status":1109,"phases":3684,"primaryCompletion":2525,"completion":1865,"start":3685,"enrollment":3686,"conditions":3687,"interventions":3688},"NCT00490074","Study to Compare the Immunogenicity and Safety of Two HIV Preventive Vaccinations in Healthy Volunteers",[88,89],"2007-07",147,[15],[3673,3689],"NYVAC-C",{"trials":3691,"activeCount":100},[],{"trials":3693,"activeCount":100},[],{"trials":3695,"activeCount":100},[],{"intervention":3689,"totalTrials":96,"cells":3697},{"EARLY_PHASE1":3698,"PHASE1":3700,"PHASE2":3702,"PHASE3":3708,"PHASE4":3710,"NA":3712},{"trials":3699,"activeCount":100},[],{"trials":3701,"activeCount":100},[],{"trials":3703,"activeCount":100},[3704],{"nctId":3682,"briefTitle":3683,"status":1109,"phases":3705,"primaryCompletion":2525,"completion":1865,"start":3685,"enrollment":3686,"conditions":3706,"interventions":3707},[88,89],[15],[3673,3689],{"trials":3709,"activeCount":100},[],{"trials":3711,"activeCount":100},[],{"trials":3713,"activeCount":100},[],{"intervention":1152,"totalTrials":96,"cells":3715},{"EARLY_PHASE1":3716,"PHASE1":3718,"PHASE2":3720,"PHASE3":3726,"PHASE4":3728,"NA":3730},{"trials":3717,"activeCount":100},[],{"trials":3719,"activeCount":100},[],{"trials":3721,"activeCount":100},[3722],{"nctId":1143,"briefTitle":1144,"status":1109,"phases":3723,"primaryCompletion":1146,"completion":1146,"start":1147,"enrollment":1148,"conditions":3724,"interventions":3725},[89],[1150,18],[1152,1153,1097],{"trials":3727,"activeCount":100},[],{"trials":3729,"activeCount":100},[],{"trials":3731,"activeCount":100},[],{"intervention":1153,"totalTrials":96,"cells":3733},{"EARLY_PHASE1":3734,"PHASE1":3736,"PHASE2":3738,"PHASE3":3744,"PHASE4":3746,"NA":3748},{"trials":3735,"activeCount":100},[],{"trials":3737,"activeCount":100},[],{"trials":3739,"activeCount":100},[3740],{"nctId":1143,"briefTitle":1144,"status":1109,"phases":3741,"primaryCompletion":1146,"completion":1146,"start":1147,"enrollment":1148,"conditions":3742,"interventions":3743},[89],[1150,18],[1152,1153,1097],{"trials":3745,"activeCount":100},[],{"trials":3747,"activeCount":100},[],{"trials":3749,"activeCount":100},[],{"intervention":3751,"totalTrials":96,"cells":3752},"dolutegravir (Tivicay®) - Phase 1",{"EARLY_PHASE1":3753,"PHASE1":3755,"PHASE2":3757,"PHASE3":3770,"PHASE4":3772,"NA":3774},{"trials":3754,"activeCount":100},[],{"trials":3756,"activeCount":100},[],{"trials":3758,"activeCount":100},[3759],{"nctId":3760,"briefTitle":3761,"status":1109,"phases":3762,"primaryCompletion":3763,"completion":3763,"start":3764,"enrollment":3765,"conditions":3766,"interventions":3767},"NCT02527096","A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)",[89],"2017-03","2015-09-17",110,[21],[3751,3768,3769],"lamivudine (Epivir®) - Phase 2","dolutegravir (Tivicay®) - Phase 2",{"trials":3771,"activeCount":100},[],{"trials":3773,"activeCount":100},[],{"trials":3775,"activeCount":100},[],{"intervention":3768,"totalTrials":96,"cells":3777},{"EARLY_PHASE1":3778,"PHASE1":3780,"PHASE2":3782,"PHASE3":3788,"PHASE4":3790,"NA":3792},{"trials":3779,"activeCount":100},[],{"trials":3781,"activeCount":100},[],{"trials":3783,"activeCount":100},[3784],{"nctId":3760,"briefTitle":3761,"status":1109,"phases":3785,"primaryCompletion":3763,"completion":3763,"start":3764,"enrollment":3765,"conditions":3786,"interventions":3787},[89],[21],[3751,3768,3769],{"trials":3789,"activeCount":100},[],{"trials":3791,"activeCount":100},[],{"trials":3793,"activeCount":100},[],{"intervention":3769,"totalTrials":96,"cells":3795},{"EARLY_PHASE1":3796,"PHASE1":3798,"PHASE2":3800,"PHASE3":3806,"PHASE4":3808,"NA":3810},{"trials":3797,"activeCount":100},[],{"trials":3799,"activeCount":100},[],{"trials":3801,"activeCount":100},[3802],{"nctId":3760,"briefTitle":3761,"status":1109,"phases":3803,"primaryCompletion":3763,"completion":3763,"start":3764,"enrollment":3765,"conditions":3804,"interventions":3805},[89],[21],[3751,3768,3769],{"trials":3807,"activeCount":100},[],{"trials":3809,"activeCount":100},[],{"trials":3811,"activeCount":100},[],{"intervention":3813,"totalTrials":96,"cells":3814},"Solo 0.3 group",{"EARLY_PHASE1":3815,"PHASE1":3817,"PHASE2":3835,"PHASE3":3837,"PHASE4":3839,"NA":3841},{"trials":3816,"activeCount":100},[],{"trials":3818,"activeCount":100},[3819],{"nctId":3820,"briefTitle":3821,"status":1109,"phases":3822,"primaryCompletion":3823,"completion":3823,"start":3824,"enrollment":3825,"conditions":3826,"interventions":3827},"NCT04842682","Dose Escalation Trial of CD40.HIVRI.Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers",[88],"2024-11-29","2021-03-29",72,[774],[3813,3828,3829,3830,3831,3832,3833,3834],"Solo 1 group","Solo 3 group","Combi 0.3 group","Combi 1 group","Combi 3 group","Late boost CD40 alone","Late boost CD40 adjuvanted",{"trials":3836,"activeCount":100},[],{"trials":3838,"activeCount":100},[],{"trials":3840,"activeCount":100},[],{"trials":3842,"activeCount":100},[],{"intervention":3828,"totalTrials":96,"cells":3844},{"EARLY_PHASE1":3845,"PHASE1":3847,"PHASE2":3853,"PHASE3":3855,"PHASE4":3857,"NA":3859},{"trials":3846,"activeCount":100},[],{"trials":3848,"activeCount":100},[3849],{"nctId":3820,"briefTitle":3821,"status":1109,"phases":3850,"primaryCompletion":3823,"completion":3823,"start":3824,"enrollment":3825,"conditions":3851,"interventions":3852},[88],[774],[3813,3828,3829,3830,3831,3832,3833,3834],{"trials":3854,"activeCount":100},[],{"trials":3856,"activeCount":100},[],{"trials":3858,"activeCount":100},[],{"trials":3860,"activeCount":100},[],{"intervention":3829,"totalTrials":96,"cells":3862},{"EARLY_PHASE1":3863,"PHASE1":3865,"PHASE2":3871,"PHASE3":3873,"PHASE4":3875,"NA":3877},{"trials":3864,"activeCount":100},[],{"trials":3866,"activeCount":100},[3867],{"nctId":3820,"briefTitle":3821,"status":1109,"phases":3868,"primaryCompletion":3823,"completion":3823,"start":3824,"enrollment":3825,"conditions":3869,"interventions":3870},[88],[774],[3813,3828,3829,3830,3831,3832,3833,3834],{"trials":3872,"activeCount":100},[],{"trials":3874,"activeCount":100},[],{"trials":3876,"activeCount":100},[],{"trials":3878,"activeCount":100},[],{"intervention":3830,"totalTrials":96,"cells":3880},{"EARLY_PHASE1":3881,"PHASE1":3883,"PHASE2":3889,"PHASE3":3891,"PHASE4":3893,"NA":3895},{"trials":3882,"activeCount":100},[],{"trials":3884,"activeCount":100},[3885],{"nctId":3820,"briefTitle":3821,"status":1109,"phases":3886,"primaryCompletion":3823,"completion":3823,"start":3824,"enrollment":3825,"conditions":3887,"interventions":3888},[88],[774],[3813,3828,3829,3830,3831,3832,3833,3834],{"trials":3890,"activeCount":100},[],{"trials":3892,"activeCount":100},[],{"trials":3894,"activeCount":100},[],{"trials":3896,"activeCount":100},[],{"intervention":3831,"totalTrials":96,"cells":3898},{"EARLY_PHASE1":3899,"PHASE1":3901,"PHASE2":3907,"PHASE3":3909,"PHASE4":3911,"NA":3913},{"trials":3900,"activeCount":100},[],{"trials":3902,"activeCount":100},[3903],{"nctId":3820,"briefTitle":3821,"status":1109,"phases":3904,"primaryCompletion":3823,"completion":3823,"start":3824,"enrollment":3825,"conditions":3905,"interventions":3906},[88],[774],[3813,3828,3829,3830,3831,3832,3833,3834],{"trials":3908,"activeCount":100},[],{"trials":3910,"activeCount":100},[],{"trials":3912,"activeCount":100},[],{"trials":3914,"activeCount":100},[],{"intervention":3832,"totalTrials":96,"cells":3916},{"EARLY_PHASE1":3917,"PHASE1":3919,"PHASE2":3925,"PHASE3":3927,"PHASE4":3929,"NA":3931},{"trials":3918,"activeCount":100},[],{"trials":3920,"activeCount":100},[3921],{"nctId":3820,"briefTitle":3821,"status":1109,"phases":3922,"primaryCompletion":3823,"completion":3823,"start":3824,"enrollment":3825,"conditions":3923,"interventions":3924},[88],[774],[3813,3828,3829,3830,3831,3832,3833,3834],{"trials":3926,"activeCount":100},[],{"trials":3928,"activeCount":100},[],{"trials":3930,"activeCount":100},[],{"trials":3932,"activeCount":100},[],{"intervention":3833,"totalTrials":96,"cells":3934},{"EARLY_PHASE1":3935,"PHASE1":3937,"PHASE2":3943,"PHASE3":3945,"PHASE4":3947,"NA":3949},{"trials":3936,"activeCount":100},[],{"trials":3938,"activeCount":100},[3939],{"nctId":3820,"briefTitle":3821,"status":1109,"phases":3940,"primaryCompletion":3823,"completion":3823,"start":3824,"enrollment":3825,"conditions":3941,"interventions":3942},[88],[774],[3813,3828,3829,3830,3831,3832,3833,3834],{"trials":3944,"activeCount":100},[],{"trials":3946,"activeCount":100},[],{"trials":3948,"activeCount":100},[],{"trials":3950,"activeCount":100},[],{"intervention":3834,"totalTrials":96,"cells":3952},{"EARLY_PHASE1":3953,"PHASE1":3955,"PHASE2":3961,"PHASE3":3963,"PHASE4":3965,"NA":3967},{"trials":3954,"activeCount":100},[],{"trials":3956,"activeCount":100},[3957],{"nctId":3820,"briefTitle":3821,"status":1109,"phases":3958,"primaryCompletion":3823,"completion":3823,"start":3824,"enrollment":3825,"conditions":3959,"interventions":3960},[88],[774],[3813,3828,3829,3830,3831,3832,3833,3834],{"trials":3962,"activeCount":100},[],{"trials":3964,"activeCount":100},[],{"trials":3966,"activeCount":100},[],{"trials":3968,"activeCount":100},[],{"intervention":3970,"totalTrials":96,"cells":3971},"Drep-HIV-PT1 0.2mg and CN54gp140\u002FMPLA-L",{"EARLY_PHASE1":3972,"PHASE1":3974,"PHASE2":3986,"PHASE3":3988,"PHASE4":3990,"NA":3992},{"trials":3973,"activeCount":100},[],{"trials":3975,"activeCount":100},[3976],{"nctId":3977,"briefTitle":3978,"status":1109,"phases":3979,"primaryCompletion":3980,"completion":3980,"start":3981,"enrollment":3344,"conditions":3982,"interventions":3983},"NCT04844775","A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults",[88],"2024-09-09","2022-08-05",[774],[3970,3984,3985],"DREP-HIV-PT1 1mg and CN54gp140\u002FMPLA-L","DNA-HIV-PT123 4mg and CN54gp140\u002FMPLA-L",{"trials":3987,"activeCount":100},[],{"trials":3989,"activeCount":100},[],{"trials":3991,"activeCount":100},[],{"trials":3993,"activeCount":100},[],{"intervention":3984,"totalTrials":96,"cells":3995},{"EARLY_PHASE1":3996,"PHASE1":3998,"PHASE2":4004,"PHASE3":4006,"PHASE4":4008,"NA":4010},{"trials":3997,"activeCount":100},[],{"trials":3999,"activeCount":100},[4000],{"nctId":3977,"briefTitle":3978,"status":1109,"phases":4001,"primaryCompletion":3980,"completion":3980,"start":3981,"enrollment":3344,"conditions":4002,"interventions":4003},[88],[774],[3970,3984,3985],{"trials":4005,"activeCount":100},[],{"trials":4007,"activeCount":100},[],{"trials":4009,"activeCount":100},[],{"trials":4011,"activeCount":100},[],{"intervention":3985,"totalTrials":96,"cells":4013},{"EARLY_PHASE1":4014,"PHASE1":4016,"PHASE2":4022,"PHASE3":4024,"PHASE4":4026,"NA":4028},{"trials":4015,"activeCount":100},[],{"trials":4017,"activeCount":100},[4018],{"nctId":3977,"briefTitle":3978,"status":1109,"phases":4019,"primaryCompletion":3980,"completion":3980,"start":3981,"enrollment":3344,"conditions":4020,"interventions":4021},[88],[774],[3970,3984,3985],{"trials":4023,"activeCount":100},[],{"trials":4025,"activeCount":100},[],{"trials":4027,"activeCount":100},[],{"trials":4029,"activeCount":100},[],{"intervention":4031,"totalTrials":96,"cells":4032},"Decitabine cycle 1",{"EARLY_PHASE1":4033,"PHASE1":4035,"PHASE2":4054,"PHASE3":4056,"PHASE4":4058,"NA":4060},{"trials":4034,"activeCount":100},[],{"trials":4036,"activeCount":100},[4037],{"nctId":4038,"briefTitle":4039,"status":1109,"phases":4040,"primaryCompletion":4041,"completion":4041,"start":4042,"enrollment":4043,"conditions":4044,"interventions":4046},"NCT05230368","Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load",[88],"2025-12-11","2022-12-14",9,[4045],"HIV-1-infection, Subtype b",[4031,4047,4048,4049,4050,4051,4052,4053],"Romidepsin cycle 1","Decitabine cycle 2","Romidepsin cycle 2","Decitabine cycle 3","Romidepsin cycle 3","Decitabine cycle 4","Romidepsin cycle 4",{"trials":4055,"activeCount":100},[],{"trials":4057,"activeCount":100},[],{"trials":4059,"activeCount":100},[],{"trials":4061,"activeCount":100},[],{"intervention":4047,"totalTrials":96,"cells":4063},{"EARLY_PHASE1":4064,"PHASE1":4066,"PHASE2":4072,"PHASE3":4074,"PHASE4":4076,"NA":4078},{"trials":4065,"activeCount":100},[],{"trials":4067,"activeCount":100},[4068],{"nctId":4038,"briefTitle":4039,"status":1109,"phases":4069,"primaryCompletion":4041,"completion":4041,"start":4042,"enrollment":4043,"conditions":4070,"interventions":4071},[88],[4045],[4031,4047,4048,4049,4050,4051,4052,4053],{"trials":4073,"activeCount":100},[],{"trials":4075,"activeCount":100},[],{"trials":4077,"activeCount":100},[],{"trials":4079,"activeCount":100},[],{"intervention":4048,"totalTrials":96,"cells":4081},{"EARLY_PHASE1":4082,"PHASE1":4084,"PHASE2":4090,"PHASE3":4092,"PHASE4":4094,"NA":4096},{"trials":4083,"activeCount":100},[],{"trials":4085,"activeCount":100},[4086],{"nctId":4038,"briefTitle":4039,"status":1109,"phases":4087,"primaryCompletion":4041,"completion":4041,"start":4042,"enrollment":4043,"conditions":4088,"interventions":4089},[88],[4045],[4031,4047,4048,4049,4050,4051,4052,4053],{"trials":4091,"activeCount":100},[],{"trials":4093,"activeCount":100},[],{"trials":4095,"activeCount":100},[],{"trials":4097,"activeCount":100},[],{"intervention":4049,"totalTrials":96,"cells":4099},{"EARLY_PHASE1":4100,"PHASE1":4102,"PHASE2":4108,"PHASE3":4110,"PHASE4":4112,"NA":4114},{"trials":4101,"activeCount":100},[],{"trials":4103,"activeCount":100},[4104],{"nctId":4038,"briefTitle":4039,"status":1109,"phases":4105,"primaryCompletion":4041,"completion":4041,"start":4042,"enrollment":4043,"conditions":4106,"interventions":4107},[88],[4045],[4031,4047,4048,4049,4050,4051,4052,4053],{"trials":4109,"activeCount":100},[],{"trials":4111,"activeCount":100},[],{"trials":4113,"activeCount":100},[],{"trials":4115,"activeCount":100},[],{"intervention":4050,"totalTrials":96,"cells":4117},{"EARLY_PHASE1":4118,"PHASE1":4120,"PHASE2":4126,"PHASE3":4128,"PHASE4":4130,"NA":4132},{"trials":4119,"activeCount":100},[],{"trials":4121,"activeCount":100},[4122],{"nctId":4038,"briefTitle":4039,"status":1109,"phases":4123,"primaryCompletion":4041,"completion":4041,"start":4042,"enrollment":4043,"conditions":4124,"interventions":4125},[88],[4045],[4031,4047,4048,4049,4050,4051,4052,4053],{"trials":4127,"activeCount":100},[],{"trials":4129,"activeCount":100},[],{"trials":4131,"activeCount":100},[],{"trials":4133,"activeCount":100},[],{"intervention":4051,"totalTrials":96,"cells":4135},{"EARLY_PHASE1":4136,"PHASE1":4138,"PHASE2":4144,"PHASE3":4146,"PHASE4":4148,"NA":4150},{"trials":4137,"activeCount":100},[],{"trials":4139,"activeCount":100},[4140],{"nctId":4038,"briefTitle":4039,"status":1109,"phases":4141,"primaryCompletion":4041,"completion":4041,"start":4042,"enrollment":4043,"conditions":4142,"interventions":4143},[88],[4045],[4031,4047,4048,4049,4050,4051,4052,4053],{"trials":4145,"activeCount":100},[],{"trials":4147,"activeCount":100},[],{"trials":4149,"activeCount":100},[],{"trials":4151,"activeCount":100},[],{"intervention":4052,"totalTrials":96,"cells":4153},{"EARLY_PHASE1":4154,"PHASE1":4156,"PHASE2":4162,"PHASE3":4164,"PHASE4":4166,"NA":4168},{"trials":4155,"activeCount":100},[],{"trials":4157,"activeCount":100},[4158],{"nctId":4038,"briefTitle":4039,"status":1109,"phases":4159,"primaryCompletion":4041,"completion":4041,"start":4042,"enrollment":4043,"conditions":4160,"interventions":4161},[88],[4045],[4031,4047,4048,4049,4050,4051,4052,4053],{"trials":4163,"activeCount":100},[],{"trials":4165,"activeCount":100},[],{"trials":4167,"activeCount":100},[],{"trials":4169,"activeCount":100},[],{"intervention":4053,"totalTrials":96,"cells":4171},{"EARLY_PHASE1":4172,"PHASE1":4174,"PHASE2":4180,"PHASE3":4182,"PHASE4":4184,"NA":4186},{"trials":4173,"activeCount":100},[],{"trials":4175,"activeCount":100},[4176],{"nctId":4038,"briefTitle":4039,"status":1109,"phases":4177,"primaryCompletion":4041,"completion":4041,"start":4042,"enrollment":4043,"conditions":4178,"interventions":4179},[88],[4045],[4031,4047,4048,4049,4050,4051,4052,4053],{"trials":4181,"activeCount":100},[],{"trials":4183,"activeCount":100},[],{"trials":4185,"activeCount":100},[],{"trials":4187,"activeCount":100},[],{"intervention":4189,"totalTrials":229,"cells":4190},"Antiretroviral",{"EARLY_PHASE1":4191,"PHASE1":4193,"PHASE2":4195,"PHASE3":4197,"PHASE4":4209,"NA":4211},{"trials":4192,"activeCount":100},[],{"trials":4194,"activeCount":100},[],{"trials":4196,"activeCount":100},[],{"trials":4198,"activeCount":100},[4199],{"nctId":4200,"briefTitle":4201,"status":193,"phases":4202,"primaryCompletion":4203,"completion":4204,"start":4205,"enrollment":4206,"conditions":4207,"interventions":4208},"NCT04051970","Reducing Antiretroviral Treatments",[90],"2023-09-01","2024-03-01","2019-11-27",360,[30],[4189],{"trials":4210,"activeCount":100},[],{"trials":4212,"activeCount":100},[4213],{"nctId":4214,"briefTitle":4215,"status":193,"phases":4216,"primaryCompletion":4217,"completion":4217,"start":4218,"enrollment":4219,"conditions":4220,"interventions":4221},"NCT04658329","Cohorte Nationale VIH-2",[],"2022-09-30","1994-01-01",1185,[2664],[4189],{"intervention":1753,"totalTrials":229,"cells":4223},{"EARLY_PHASE1":4224,"PHASE1":4226,"PHASE2":4228,"PHASE3":4230,"PHASE4":4236,"NA":4238},{"trials":4225,"activeCount":100},[],{"trials":4227,"activeCount":100},[],{"trials":4229,"activeCount":100},[],{"trials":4231,"activeCount":100},[4232],{"nctId":1744,"briefTitle":1745,"status":193,"phases":4233,"primaryCompletion":1747,"completion":1748,"start":1449,"enrollment":1749,"conditions":4234,"interventions":4235},[89,90],[1751,24],[1753,1733],{"trials":4237,"activeCount":100},[],{"trials":4239,"activeCount":100},[4240],{"nctId":4241,"briefTitle":4242,"status":193,"phases":4243,"primaryCompletion":4244,"completion":4244,"start":4245,"enrollment":4246,"conditions":4247,"interventions":4248},"NCT02624453","Pre-Antiretroviral Therapy (ART) Cryptococcal Antigen Screening in AIDS",[92],"2018-03","2015-07",186,[1751],[1753,4249],"Antiretroviral therapy",{"intervention":4251,"totalTrials":96,"cells":4252},"Blood sample",{"EARLY_PHASE1":4253,"PHASE1":4255,"PHASE2":4257,"PHASE3":4259,"PHASE4":4261,"NA":4263},{"trials":4254,"activeCount":100},[],{"trials":4256,"activeCount":100},[],{"trials":4258,"activeCount":100},[],{"trials":4260,"activeCount":100},[],{"trials":4262,"activeCount":100},[],{"trials":4264,"activeCount":100},[4265],{"nctId":4266,"briefTitle":4267,"status":193,"phases":4268,"primaryCompletion":4269,"completion":4270,"start":4271,"enrollment":4272,"conditions":4273,"interventions":4275},"NCT03354936","ANRS CO24 OncoVIHAC (Onco VIH Anti Checkpoint)",[],"2022-01-01","2022-06-15","2018-01-17",50,[4274],"HIV Infected Patients With Cancer Treated by ICPi",[4251],{"intervention":4277,"totalTrials":96,"cells":4278},"Immediate ARV treatment initiation with TDF\u002FFTC\u002FEFV",{"EARLY_PHASE1":4279,"PHASE1":4281,"PHASE2":4283,"PHASE3":4285,"PHASE4":4287,"NA":4289},{"trials":4280,"activeCount":100},[],{"trials":4282,"activeCount":100},[],{"trials":4284,"activeCount":100},[],{"trials":4286,"activeCount":100},[],{"trials":4288,"activeCount":100},[],{"trials":4290,"activeCount":100},[4291],{"nctId":4292,"briefTitle":4293,"status":1109,"phases":4294,"primaryCompletion":4295,"completion":4295,"start":2134,"enrollment":4296,"conditions":4297,"interventions":4298},"NCT01509508","Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence",[92],"2016-06",28153,[18],[4277],{"intervention":4249,"totalTrials":96,"cells":4300},{"EARLY_PHASE1":4301,"PHASE1":4303,"PHASE2":4305,"PHASE3":4307,"PHASE4":4309,"NA":4311},{"trials":4302,"activeCount":100},[],{"trials":4304,"activeCount":100},[],{"trials":4306,"activeCount":100},[],{"trials":4308,"activeCount":100},[],{"trials":4310,"activeCount":100},[],{"trials":4312,"activeCount":100},[4313],{"nctId":4241,"briefTitle":4242,"status":193,"phases":4314,"primaryCompletion":4244,"completion":4244,"start":4245,"enrollment":4246,"conditions":4315,"interventions":4316},[92],[1751],[1753,4249],{"intervention":4318,"totalTrials":96,"cells":4319},"PrEP with Truvada®",{"EARLY_PHASE1":4320,"PHASE1":4322,"PHASE2":4324,"PHASE3":4326,"PHASE4":4328,"NA":4330},{"trials":4321,"activeCount":100},[],{"trials":4323,"activeCount":100},[],{"trials":4325,"activeCount":100},[],{"trials":4327,"activeCount":100},[],{"trials":4329,"activeCount":100},[],{"trials":4331,"activeCount":100},[4332],{"nctId":4333,"briefTitle":4334,"status":193,"phases":4335,"primaryCompletion":890,"completion":4336,"start":4337,"enrollment":4338,"conditions":4339,"interventions":4340},"NCT03113123","Prevention of HIV in \"Île-de-France\"",[92],"2024-10","2017-05-03",3257,[15],[4318],{"intervention":4342,"totalTrials":96,"cells":4343},"HCV treatment",{"EARLY_PHASE1":4344,"PHASE1":4346,"PHASE2":4348,"PHASE3":4350,"PHASE4":4352,"NA":4354},{"trials":4345,"activeCount":100},[],{"trials":4347,"activeCount":100},[],{"trials":4349,"activeCount":100},[],{"trials":4351,"activeCount":100},[],{"trials":4353,"activeCount":100},[],{"trials":4355,"activeCount":100},[4356],{"nctId":4357,"briefTitle":4358,"status":1109,"phases":4359,"primaryCompletion":4360,"completion":4360,"start":4361,"enrollment":4362,"conditions":4363,"interventions":4364},"NCT04008927","A Community-based Intervention Among Active Drug Users in Montpellier",[92],"2021-09-10","2020-09-18",554,[1180,869],[4342],{"intervention":4366,"totalTrials":96,"cells":4367},"A sample of venous blood will also be collected",{"EARLY_PHASE1":4368,"PHASE1":4370,"PHASE2":4372,"PHASE3":4374,"PHASE4":4376,"NA":4378},{"trials":4369,"activeCount":100},[],{"trials":4371,"activeCount":100},[],{"trials":4373,"activeCount":100},[],{"trials":4375,"activeCount":100},[],{"trials":4377,"activeCount":100},[],{"trials":4379,"activeCount":100},[4380],{"nctId":4381,"briefTitle":4382,"status":1109,"phases":4383,"primaryCompletion":3076,"completion":3076,"start":4384,"enrollment":3411,"conditions":4385,"interventions":4386},"NCT01038401","Residual Replication of HIV-1 in the Gut Associated Lymphoid Tissue (GALT) of Patients on Highly Active Antiretroviral Therapy (HAART): the ANRS EP 44 Study",[92],"2008-09",[18],[4366],{"intervention":4388,"totalTrials":96,"cells":4389},"blood sampling,",{"EARLY_PHASE1":4390,"PHASE1":4392,"PHASE2":4394,"PHASE3":4396,"PHASE4":4398,"NA":4400},{"trials":4391,"activeCount":100},[],{"trials":4393,"activeCount":100},[],{"trials":4395,"activeCount":100},[],{"trials":4397,"activeCount":100},[],{"trials":4399,"activeCount":100},[],{"trials":4401,"activeCount":100},[4402],{"nctId":4403,"briefTitle":4404,"status":1109,"phases":4405,"primaryCompletion":1553,"completion":1553,"start":2038,"enrollment":4406,"conditions":4407,"interventions":4409},"NCT01899196","Epicardial Adipose Tissue And Coronary Risk In HIV-Infected Patients",[92],24,[4408],"Hiv Infection",[4388],{"intervention":4411,"totalTrials":96,"cells":4412},"COVID-19 vaccine",{"EARLY_PHASE1":4413,"PHASE1":4415,"PHASE2":4417,"PHASE3":4419,"PHASE4":4421,"NA":4423},{"trials":4414,"activeCount":100},[],{"trials":4416,"activeCount":100},[],{"trials":4418,"activeCount":100},[],{"trials":4420,"activeCount":100},[],{"trials":4422,"activeCount":100},[],{"trials":4424,"activeCount":100},[4425],{"nctId":4426,"briefTitle":4427,"status":193,"phases":4428,"primaryCompletion":4429,"completion":4429,"start":4430,"enrollment":4431,"conditions":4432,"interventions":4434},"NCT04824651","Covid-19 Vaccine Cohort in Specific Populations",[],"2024-06-25","2021-03-25",6920,[4433],"Immune Deficiency",[4411],{"intervention":4436,"totalTrials":96,"cells":4437},"HIV prevention package including PrEP",{"EARLY_PHASE1":4438,"PHASE1":4440,"PHASE2":4442,"PHASE3":4444,"PHASE4":4446,"NA":4448},{"trials":4439,"activeCount":100},[],{"trials":4441,"activeCount":100},[],{"trials":4443,"activeCount":100},[],{"trials":4445,"activeCount":100},[],{"trials":4447,"activeCount":100},[],{"trials":4449,"activeCount":100},[4450],{"nctId":4451,"briefTitle":4452,"status":1109,"phases":4453,"primaryCompletion":4454,"completion":3560,"start":4455,"enrollment":4456,"conditions":4457,"interventions":4458},"NCT03459157","Access to PrEP for MSM: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP)",[92],"2020-12-23","2017-11-20",649,[268],[4436],{"intervention":4460,"totalTrials":96,"cells":4461},"blood drawn",{"EARLY_PHASE1":4462,"PHASE1":4464,"PHASE2":4466,"PHASE3":4468,"PHASE4":4470,"NA":4472},{"trials":4463,"activeCount":100},[],{"trials":4465,"activeCount":100},[],{"trials":4467,"activeCount":100},[],{"trials":4469,"activeCount":100},[],{"trials":4471,"activeCount":100},[],{"trials":4473,"activeCount":100},[4474],{"nctId":4475,"briefTitle":4476,"status":193,"phases":4477,"primaryCompletion":4478,"completion":4479,"start":4480,"enrollment":4481,"conditions":4482,"interventions":4483},"NCT03622177","Role of the IL33\u002FAmphiregulin Pathway as a Potential Therapeutic Target in HIV Infection",[],"2019-09","2023-09","2018-09",180,[439],[4460],{"intervention":4485,"totalTrials":96,"cells":4486},"Treatment initiation for HIV-1 group O infected patients",{"EARLY_PHASE1":4487,"PHASE1":4489,"PHASE2":4491,"PHASE3":4493,"PHASE4":4495,"NA":4497},{"trials":4488,"activeCount":100},[],{"trials":4490,"activeCount":100},[],{"trials":4492,"activeCount":100},[],{"trials":4494,"activeCount":100},[],{"trials":4496,"activeCount":100},[],{"trials":4498,"activeCount":100},[4499],{"nctId":4500,"briefTitle":4501,"status":1109,"phases":4502,"primaryCompletion":4503,"completion":1748,"start":4504,"enrollment":4505,"conditions":4506,"interventions":4507},"NCT00658346","Molecular Diversity of HIV-1 Group O Strains and Treatment Management in Cameroon",[],"2015-08","2010-06",141,[15],[4485,4508],"Treatment initiation for HIV-1 group M infected patients",{"intervention":4508,"totalTrials":96,"cells":4510},{"EARLY_PHASE1":4511,"PHASE1":4513,"PHASE2":4515,"PHASE3":4517,"PHASE4":4519,"NA":4521},{"trials":4512,"activeCount":100},[],{"trials":4514,"activeCount":100},[],{"trials":4516,"activeCount":100},[],{"trials":4518,"activeCount":100},[],{"trials":4520,"activeCount":100},[],{"trials":4522,"activeCount":100},[4523],{"nctId":4500,"briefTitle":4501,"status":1109,"phases":4524,"primaryCompletion":4503,"completion":1748,"start":4504,"enrollment":4505,"conditions":4525,"interventions":4526},[],[15],[4485,4508],{"intervention":4528,"totalTrials":96,"cells":4529},"A peripheral blood sample",{"EARLY_PHASE1":4530,"PHASE1":4532,"PHASE2":4534,"PHASE3":4536,"PHASE4":4538,"NA":4540},{"trials":4531,"activeCount":100},[],{"trials":4533,"activeCount":100},[],{"trials":4535,"activeCount":100},[],{"trials":4537,"activeCount":100},[],{"trials":4539,"activeCount":100},[],{"trials":4541,"activeCount":100},[4542],{"nctId":4543,"briefTitle":4544,"status":1109,"phases":4545,"primaryCompletion":2309,"completion":2309,"start":1135,"enrollment":2041,"conditions":4546,"interventions":4547},"NCT01952587","X-linked Biological Response to HIV Sensing: the ANRS EP 53 Study",[92],[4408],[4528]]